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Abstract 
Pin1 is a human protein classified as a peptidyl-prolyl cis/trans isomerase.  The protein 
regulates the conformation of phosphorylated protein substrates by rotating the peptide bond 
between phosphorylated serine/threonine residues that precede proline residues. Structurally, 
Pin1 consists of an N-terminal WW domain and a C-terminal PPIase domain.  The PPIase 
domain catalyzes cis/trans isomerization of peptide bonds in substrate proteins that contain the 
aforementioned consensus motif.  We hypothesize that Pin1 binding is positively impacted when 
two phospho-acceptor sites on peptides derived from mitotic phosphatase CDC25C, a known 
Pin1-interacting protein, are phosphorylated. Using nuclear magnetic resonance and fluorescence 
polarization, binding affinities of CDC25C peptides to Pin1 were calculated. The results indicate 
that doubly-phosphorylated peptides bound to Pin1 have lower dissociation constants and 
consequently greater binding affinities, than complexes containing non- or singly-phosphorylated 
peptides, at the equivalent residues. This suggests that Pin1 has two independent phospho-
binding sites that when bound, increase substrate binding affinity.  
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1. Introduction 
Cell homeostasis is a key feature involved in the maintenance of healthy cells; 
therefore signalling pathways that respond to external stimuli in the changing 
environment are tightly regulated. An extensive network of cellular proteins is implicated 
in these signal transduction cascades, including protein kinases that phosphorylate 
substrate proteins, and other proteins that elicit responses through modifications of 
substrate proteins pre- or post-phosphorylation
1
. One such modification is the 
isomerization of peptide bonds
2-5
. 
Peptide bonds have been shown to exhibit partial double bond characteristics and 
can therefore exist in one of two conformations: cis or trans
6
. Isomerases are enzymes 
that catalyze the interconversion of peptide bond isoforms; further, isomerization is a 
mechanism for higher-order regulation
7-10
. The majority of peptide bonds occur in trans 
in proteins, as trans isomers tend to be more stable due to the separation of large 
functional groups in space, which disables steric hindrance
11
. In contrast, the bonds 
preceding a proline (Pro) residue often appear in the cis conformation as a result of the 
restrictive cyclic structure of Pro and the symmetry of the carbon atoms within the ring
12
. 
The phenomenon of cis bond isomers occurs in approximately 30% of peptides and 10% 
of proteins, compared to their corresponding trans isomers
13
. The interconversion 
between the two peptide bond isoforms is a slow process if un-catalyzed, hence the utility 
of peptidyl-prolyl isomerases (PPIase), a specific class of isomerase, that increases the 
rate of bond interconversion for peptide bond conformations proximal to Pro residues. 
2 
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1.1 Peptidyl-prolyl isomerases 
There are three families of PPIases: cyclophilins (CyPs), FK506-binding proteins 
(FKBPs) and parvulins. Several members of these protein families have been identified 
as targets for the development of immunosuppressive drugs including CyPs and FKBPs, 
which have been identified as the targets of cyclosporin and rapamycin respectively.  
Similar to parvulins, both the CyPs and the FKBPs are able to catalyze peptidyl-prolyl 
isomerization; however their sequences and structures show no noticeable similarities. 
Each of the three enzyme families has a different recognition motif for residues preceding 
a proline
14-18
. The parvulin family, so named because of the small size of the proteins, has 
two protein sub-classes: the non-Pin1 parvulins and the Pin1-like parvulins. The non-Pin1 
sub-class can isomerize the peptide bond between a non-phosphorylated residue 
preceding a Pro, while the Pin1-like parvulins isomerize the peptide bond between a 
phosphorylated residue preceding a Pro
17
 (Figure 1). Mechanistically, Pin1 has a proline-
directed function that acts on phosphorylated serine/threonine (pSer/Thr) substrates
19
 and 
its phosphorylation-dependence is what makes Pin1 unique amongst its class of 
enzymes
20
. 
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Figure 1 The cis-trans isomerization reaction catalyzed by Pin1. 
Cis-trans isomerization is a slow process if uncatalyzed. Peptidyl-prolyl isomerases 
accelerate this process. Pin1 is a phosphorylation-dependent PPIase with a proline-
directed function that acts on phosphorylated Ser/Thr substrates preceding a Pro residue. 
The other PPIases, Cyps, FKBPs and non Pin1-like parvulins, isomerize the peptide bond 
between a non-phosphorylated residue preceding a Pro. 
Figure 1 
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1.2 Introduction to Pin1 
Pin1 is a peptidyl-prolyl isomerase that catalyzes the interconversion between cis 
and trans isomers of a peptide bond.  It specifically binds to phosphorylated substrates 
preceding a Pro residue and regulates their isomeric conformation. The enzymatic 
isomerization function of Pin1 was originally discovered after the protein was observed 
to interact with the protein encoded by Never in Mitosis gene A (NIMA), a protein kinase 
involved in the regulation of mitosis. The protein interaction was identified using a yeast 
two hybrid screen and many similar proteins have since been identified in other 
eukaryotic organisms and some prokaryotes
21
. The Pin1 homolog in yeast, ESS1, was 
discovered in 1989
22
 before the discovery of Pin1 in humans, by the Hunter lab in 1996
21
. 
Human Pin1 is an essential protein
23
 and contains 45% sequence identity to its yeast 
homolog, which is known to be an essential protein for growth in yeast
22
. A role for Pin1 
was first identified in mitotic regulation, but it is now known that Pin1 catalyzes the 
isomerization of proteins involved in many different cellular processes, including 
apoptosis, cell cycle progression, cell survival and proliferation, DNA repair, stress 
responses and transcription
8,24-30
.  
1.3 Pin1 in the cell 
The activity of Pin1 can be regulated post-translationally, through 
phosphorylation by protein kinases, and by oxidation.  The reduction and oxidation of 
Pin1 has been studied in relation to its role in Alzheimer’s disease31. Ser residues 16 and 
65 can both be phosphorylated, to decrease substrate binding or to increase protein 
stability by reducing the occurrence of further modifications on the site19,32. Pin1 is 
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localized in vitro to the nucleus and the cytoplasm, with the former being its predominant 
location
21,33
.  
To date, Pin1 is the only known peptidyl-prolyl cis/trans isomerase that functions 
as a phosphorylation-directed enzyme
34
.  It regulates conformational changes for many 
substrate proteins involved in signalling pathways that mediate cancers and 
neurodegenerative diseases
26,35-39
.  For example, Pin1 interacts with Cyclin D1, a protein 
that forms a complex with cyclin-dependent kinases and functions as a regulatory subunit 
in the G1 to S phase transition of the cell cycle
40
. Once bound, Cyclin D1 transcription is 
increased because Pin1 can promote upstream signalling factors. This includes Jun N-
terminal kinases, which generate phosphorylated c-Jun to stimulate further transcription 
of Cyclin D1. Cyclin D1 is also unable to exit the nucleus and therefore unable to be 
targeted to the proteasome for degradation
41
. Other Pin1 interacting proteins that regulate 
Cyclin D1 transcription are β-catenin and NFκB42,43.  Pin1 disables the re-generation of 
β-catenin and targets it to the nucleus where it can promote the transcription of other 
genes.  The p65/RelA binding site located on NFκB undergoes isomerization by Pin1 and 
the conformational change detaches NFκB from an inhibitor enabling nuclear targeting. 
Once in the nucleus, NFκB aids in promoting Cyclin D1 transcription. E2F transcription 
as well as cell cycle progression is regulated by Cyclin D1 and is positively controlled by 
Pin1. This feedback mechanism is used in cancerous tumours from mouse models by the 
proteins Her2/Neu and Ras to stimulate continuous cell growth in mammary epithelial 
cells
44
. For this purpose, the inhibition or down regulation of Pin1 could effectively target 
cancers evading multiple pathways. In addition to the above-mentioned example, 
6 
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previous studies have also identified a variety of other cellular proteins that interact with 
Pin1 including: Akt
45
, Bcl-2
46
, Cdc25
47
, P53
48
 and Tau
49
. 
1.4 Role of Pin1 in pathogenesis 
Pin1 is implicated in two well-studied, yet diverse diseases: Alzheimer’s disease 
(AD) and cancer. This is not surprising due to the known proteins and pathways in which 
Pin1 has been associated. The protein induces opposing effects in AD and cancer, based 
on its expression and amount of enzymatic activity.  
1.4.1 Decrease of Pin1 in neurodegeneration 
Various studies have implicated Pin1 in neurogenesis
50
.  Pin1 knockout mice have 
shown prognostic AD markers
51
 and decreases in cellular Pin1 protein levels contribute 
to AD through effects on the Tau protein and the amyloid precursor protein (APP)
52
. 
Tau is implicated in AD because when the protein is inactivated, microtubule 
stabilization is affected. Pin1 interacts with Tau after Tau is phosphorylated on residues 
Thr212 and Thr231
49,53
. Following this, pThr231 becomes dephosphorylated by PP2A, a 
phosphatase that acts to specifically dephosphorylate trans conformational bonds, and 
Tau can begin to stabilize microtubules. In the neurons, when Tau becomes hyper-
phosphorylated through a lack of Pin1 and PP2A function, neurofibrillary tangles can 
form
53
.  These tangles are common occurrences in the process of neurodegeneration. 
A second common occurrence in neurodegenerative disorders is the formation of 
senile plaques in the brain. These plaques are composed of insoluble amyloid-β (Aβ) 
peptides, which are generated from APP
54
.   Pin1 interactions with the binding motif 
pThr668-Pro of APP help to regulate the amount of Aβ peptides generated. Once Pin1 is 
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bound to APP, the peptidyl-prolyl isomerization is increased by over 1000-fold
54
. The cis 
isoform of APP is responsible for the increase of insoluble Aβ peptides which can 
accumulate into plaques in the brain
55
. Pin1 is accountable for the cis to trans conversion 
of APP and if Pin1 is down-regulated, the pathogenic cis isoform of APP becomes 
dominant
54
. 
1.4.2 Pin1 overexpression in cancer 
The effects of Pin1 in cancer are contrasting to those of AD.  For one, Pin1 is 
down-regulated in AD and its depletion leads to cell death
56
, while the protein is up-
regulated in cancer and postulated to promote tumour growth
19
. Pin1 has a role in many 
forms of cancer including breast
57
, cervical
58
, colon
59
, liver
60
, lung
61
, oral squamous
62
, 
head and neck cancers
63
 and prostate cancer
64
 (see 
65
 for a general overview). Upon 
further characterization, Pin1 overexpression has been implicated as a marker for poor 
prognosis and a higher likelihood of recurrence in prostate cancer
64
. Cancerous tumours 
displayed overexpression of Pin1 at the mRNA as well as the protein level
41
.  
Pin1 has been well studied in tumours generated through the dysregulation of 
Her2/ Neu or Ras protein-implicated pathways
44,66,67
. Using mouse models, studies have 
shown that Pin1 overexpression increases the oncogenic effects of Neu and Ras, whereas 
mice lacking Pin1 do not exhibit such effects. These proteins affect E2F, a transcription 
factor, which leads to as increase in Cyclin D1 and Pin1 in cells
44,68
.  
Overall, in the context of cancer Pin1 inhibits tumour suppressors by changing the 
conformation of a substrate so that its activator cannot bind
69
. In addition, Pin1 stabilizes 
the extensively studied tumour suppressor p53, a key protein that stimulates apoptosis 
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under cell stress conditions
70
.  Pin1 has therefore been recognized as a potential 
therapeutic target because of its diverse implications in disease. 
1.5 Pin1 as a therapeutic target 
Pin1 was originally revealed to regulate key players in mitosis, but through 
further characterization Pin1 has been presented in many other complex processes
26,71,72
.  
The phosphorylation-specific nature of Pin1 adds an increased level of regulation in 
relation to Pro-directed enzymes, such as kinases, needed for cellular processes
73
. Of note 
is the association of Pin1 with proteins involved in cancer, and Alzheimer’s disease. As a 
result, Pin1 is a potential candidate for the development of targeted therapeutics. The 
other PPIase protein families, cyclophilins and FKBPs, both have drugs associations that 
act in an inhibitory manner to decrease protein activity
74,75
. The compound juglone, a 
naturally occurring compound, was isolated as a parvulin family inhibitor. This molecule 
was able to inhibit Pin1 and other parvulins, through an interaction with Cys113. 
Unfortunately, the lack of specificity towards Pin1 and the potential for off-target effects 
on cellular proteins (including RNA polymerases) disabled juglone from becoming a 
therapeutic agent for cancer treatment
76
. Therefore, targeted therapeutics towards Pin1 
have been focused on the active site Cys residue, the hydrophobic pocket or the 
phosphate binding loop
72,77,78
. Structure-based inhibitor design is a commonly used 
method, but many of the isolated compounds contained phosphate moieties to increase 
their binding affinity, which in turn decreased their cell membrane permeability. To 
circumvent this setback, work in the Litchfield lab used phage display to identify peptide 
sequences that inhibit Pin1. The screen was directed towards identifying cyclic peptides 
that would inhibit the PPIase domain of the protein, to decrease its function and 
9 
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potentially act as a cancer therapeutic. The cyclic peptides were shown to bind with a 
high affinity to Pin1, potentially due to their rigidity, and the cyclic peptides may also 
have the ability to evade proteolysis
79
. In order to generate potent inhibitors, it is 
important to understand the mechanism by which Pin1 binds to its substrates and the 
corresponding affinities.  With Pin1 having two domains for binding, and knowing that 
Pin1 substrates may themselves have multiple binding sites increases complexity within 
the in vitro system.   
1.6 Structural features of Pin1 
Pin1 is a small 18.4 kDa protein, consisting of 163 amino acids in length
21
. It has 
two diverse structural domains, as determined by X-ray crystallography
45
: an N-terminal 
type IV WW domain, so named for its conserved tryptophan residues located at amino 
acid positions 11 and 34, and a C-terminal PPIase enzymatic domain
74,80
. The domains 
are separated by a flexible linker of ten residues in length, between residues 1-39 of the 
WW domain and residues 50-163 of the isomerase domain (Figure 2)
81
. Both domains 
recognize similar motifs containing phospho-Ser/Thr-Pro
82
. Proline-directed binding and 
isomerization are both well-known mechanisms for post-phosphorylation regulation and 
have been extensively studied
73,83,84
.  
The secondary structure of Pin1 consists of three anti-parallel β-sheets in the WW 
domain, which contains a hydrophobic area on its surface. The PPIase domain has four α-
helices and three anti-parallel β-sheets in its secondary structure. Two characterized 
regions are also located in the PPIase domain: a proline binding pocket and a phosphate 
binding loop
85
. These known structural areas are located on opposing sides of the active 
site of the protein, which is centered on Cys residue 113 (Figure 2 - bottom panel). Other 
10 
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active site amino acids include His 59, His 157 and Ser 154
86
. These residues arrange into 
a pocket in which a substrate peptide bond can enter (1PIN structure and Figure 2)
45
. The 
proline binding pocket is a hydrophobic groove with conserved leucine (Leu), methionine 
(Met) and phenylalanine (Phe) residues (Leu122, Met130 and Phe134). The phosphate 
binding loop contains positively charged residues that can interact with a negatively 
charged phosphate moiety. Lys63, Arg68 and Arg69 are the central amino acids 
coordinating this binding
87
. 
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Figure 2 
 
 
 
 
 
 
Figure 2 Surface covered ribbon representation of the x-ray crystallography 
reference structure of Pin1. 
Pymol-generated image of the surface and ribbon structure of Pin1, using the R14A Pin1 
crystal structure (Protein Data Bank Code 1PIN). The WW domain, residues 1-39, is 
visible in red with the characteristic Trp11 (left panel) and Trp34 (right panel) coloured 
in cyan. This domain has three anti-parallel β-sheets. The PPIase domain, residues 50-
163, is coloured in blue and is comprised of four α-helices and three anti-parallel β-
sheets. The left panel image is rotated along the vertical axis by 180ᴼ to show the right 
panel. The bottom surface view is shown by rotating the left panel image along the 
horizontal axis by 90ᴼ.  The protein active site, located in the isomerase domain, is 
coloured in green and is composed of amino acid residues (H59, L60, L61, V62, K63, 
R68, R69, A85, I89, C113, L122, S154, I156 and H157) centered on the catalytic 
Cys113. 
12 
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 In binding, the WW domain of Pin1 is known to bind to substrates with a higher 
affinity than the PPIase domain. The residues from this domain involved in substrate 
binding are: Arg17, Tyr23 and Trp34. This domain enhances substrate specificity when a 
binding motif is located on a peptide
88
. The WW domain of Pin1 has been shown to have 
a ten-fold higher binding affinity for a known Pin1 substrate, Pintide (WFYpSPR-NH2) 
compared to the PPIase protein domain
88
.  The WW domain has a high affinity for most 
substrates and  it is therefore thought to be responsible for substrate targeting and 
recognition whereas, the PPIase domain alone is usually unable to bind known substrates, 
but takes on the role of catalyzing imide bond isomerization
89
.  
Many of the Pin1-interacting proteins have one binding site identified, whereas 
some may contain multiple binding sites. In the latter case, these sites are separated by 
approximately 19 amino acid residues within the protein sequence
29,52
.  This separation is 
intriguing and may be related to the spacing between the two domains in Pin1. The 
downstream binding site could bind to the WW domain and the upstream site could bind 
and/ or undergo isomerization by the PPIase domain. One such example of the multiple 
binding sites occurs in the protein Tau, a protein found in neural tissues, and another is 
CDC25C, a mitotic initiator protein. In the aforementioned proteins, there are two Pin1 
binding sites separated by 19 amino acids
24,52
.  
Studies conducted by Smet et al.
90
 used peptides derived from the protein Tau. 
One of the peptides contained two phosphorylation sites separated by two amino acids. 
Another contained three phosphorylation sites, the two previously mentioned and the 
third separated by 16 residues. The first and third phosphorylated residues are each part 
of a Pin1 binding motif. Results show that two Pin1 binding motifs on a peptide increase 
13 
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the protein-peptide binding affinity but decrease the peptide isomerization rate
90
. From 
this work, two unresolved questions arose: does cooperativity occur between peptide 
binding motifs interacting with Pin1, and do the two Pin1 domains cooperate during 
substrate binding? 
1.7 Pin1 catalytic mechanism 
Based on structural studies, Ranganathan et al.
45
 proposed that the catalytic 
mechanism of Pin1 involves covalent binding, where Pin1 binds to a ligand and adopts a 
tetrahedral intermediate conformation
45
. The phosphorylated residue on the substrate fits 
into the binding pocket for isomerization and the peptide bond is shifted by 90 degrees to 
move the carbonyl oxygen away from the active site of Pin1.  With this movement, the 
side chain of residue Cys113 of Pin1 can enter the protein active site. His59, another 
residue located in proximity to the active site, deprotonates Cys113 priming it for a 
nucleophilic attack on the carbonyl carbon atom of the substrate. The carbonyl oxygen of 
the substrate is negatively charged and can be modulated by His157. The intermediate 
species is then abolished allowing for the discharge of the substrate
45
.  
In 2000, this mode of substrate catalysis was questioned when the structure of a 
Pin1 homologue in Arabidopsis thaliana was determined by solution-state NMR
91
.  The 
Cys113 equivalent residue in the plant organism exhibited minimal motion when bound 
to a ligand. This finding contradicted previous reports of covalent binding
92
.  Using an 
approach comprising mutagenesis and peptidyl-prolyl isomerization activity assays, the 
Litchfield lab displayed that a non-covalent mechanism was likely the mode of binding 
used for Pin1-substrate interactions
77
. A unigenic evolution study conducted by Behrsin 
et al. invalidated the nucleophilic tendencies of Cys113
77
.   In this paper, the Cys residue 
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was mutated to a Ser in order to retain nucleophilic tendencies; however, this mutation 
disabled Pin1 catalytic activity. On the other hand, when the residue was mutated to an 
Asp catalytic activity was only reduced. The enzymatic activity of Pin1 is therefore 
mediated by factors such as charge
77
.  
Continued efforts to elucidate the catalytic mechanism of Pin showed that the two 
His residues located near the binding pocket, His59 and His157, are needed to increase 
protein stability
86
. These residues, previously thought to engage in hydrogen bonding, 
were mutated into Leu residues. This revealed that proton donors were not required for 
binding. The His59Leu mutation caused the protein to become inactive, but when 
His157Leu was introduced in conjunction with His59Leu, protein catalytic activity was 
restored. Further, a different isomerization mechanism was suggested in 2008 because of 
the negative charge surrounding the Pin1 active site Cys
86
.  
Most PPIases use the bond-distortion mechanism for substrate catalysis, which is 
similar to that hypothesized for Pin1. The active site environment results in a low pKa for 
Cys113.  Consequently, at neutral pH the partial negative charge on cysteine enables the 
stabilization of the carbonyl group on the substrate. The substrate carbonyl group exhibits 
double-bond rigidity and if a resonance structure were to form, the peptide bond to be 
isomerized would become rigid and impact cis/trans changes
93
.   
1.8 Binding models 
Pin1 is able to bind to phosphorylated motifs through both of its structural 
domains. The domains can bind concurrently or separately to specific protein substrates 
that contain the sequence motif pSer/Thr-Pro.  For this reason, the mode of binding for 
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Pin1 to substrates remains unknown. To date, there are four potential binding 
mechanisms modeled for Pin1 binding and peptidyl-prolyl isomerization (Figure 3). The 
catalysis-first binding model begins with the PPIase domain binding to a cis isomer to 
isomerize the bond and convert it into trans. From there the WW domain, known to bind 
preferentially to trans isoforms, can favourably bind to the substrate
94
 (Figure 3A). A 
second model is the multimeric model in which Pin1 is part of a complex of proteins. 
Since the WW domain binds preferentially to most substrates, it is likely that the domain 
binds a protein as part of the complex. This leaves the enzymatic domain free to 
isomerize a ligand
36
 (Figure 3B).  The sequential model for Pin1 binding suggests that 
the WW domain binds to its target sequence first. Then, the PPIase domain is able to 
bind, at the same site or an adjacent site, for isomerization (Figure 3C). This model 
seems preferential in the case of Pin1 interactors containing multiple binding motifs. 
Some examples of proteins with greater than one Pin1 target sequence include: CDC25C, 
CK2 and Tau
35
. The simultaneous binding model is the fourth method recently proposed 
in the literature. This method involves multi-phosphorylated substrates that can be bound 
by both Pin1 domains independently yet synchronously to increase substrate affinity
95
 
(Figure 3D).  
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Figure 3 (A-D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Illustrative representation of Pin1 binding models. 
A) The catalysis-first binding model: The PPIase domain of Pin1 binds to a 
pSer/Thr-Pro motif in the cis isoform to isomerize the peptide bond. The WW 
domain can then preferentially bind to the trans substrate. 
B) The multimeric binding model: Pin1 is involved in a protein complex 
through WW domain interactions. The PPIase domain is able to isomerize a 
substrate in close proximity.  
C) The sequencial binding model: The WW domain of Pin1 can first bind to a 
pSer/Thr-Pro motif and then the PPIase domain is able to bind to the substrate, 
at the same site or an adjacent site, for isomerization.  
D) The simultaneous binding model: Both Pin1 domains can bind to a substrate 
containing multiple pSer/Thr-Pro binding motifs. Each domain may have a low 
affinity for the site, but together this binding can increase the affinity.  
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Pin1 itself is phosphorylated which can act to inhibit its isomerization 
capabilities
96
. In other cases, Pin1 phosphorylation has no effect on its interaction with 
proteins involved in key regulatory processes
45-48,61,97
. One such example of a Pin1-
interacting protein is human CDC25C. Through the interaction between Pin1 and 
CDC25C, Pin1 is associated with eukaryotic entry into mitosis. Once Pin1 isomerization 
occurs on its substrate CDC25C, the substrate then dephosphorylates CDC2 which can 
form an active complex with Cyclin B. The activated protein complex stimulates a 
decrease in mitotic entry
98
.  
1.9 CDC25C and Pin1 as a system for this study 
In order to elucidate the roles of Pin1 with respects to function and pathogenesis, 
researchers began to look at protein interactions. Many proteins known to be implicated 
in diverse cellular processes were found to associate directly or indirectly with 
Pin1
24,44,67,69,99-103
 and a few undergo conformational changes upon interaction
8,23,24,35
. 
The association between  human CDC25C and Pin1, discovered in 1998
23
,  was later 
shown to affect the conformation of the Pin1 substrate
24
. CDC25C is a phosphatase with 
considerable sequence similarity between the human and Xenopus forms and is required 
for mitotic initiation. Many post-translational modifications affect this protein to regulate 
its function in the triggering of mitotic events. In order to initiate mitosis, CDC25C is 
activated by hyper-phosphorylation
103
. In contrast to CDC25C, most phosphatases act to 
reverse the process of phosphorylation and generate opposing effects. In the case of 
CDC25C, Pin1 binding to the phosphorylated residues Thr48 and Thr67, in the regulatory 
N-terminus of the protein, affects the conformation of CDC25C and enables subsequent 
dephosphorylation
24
. This two-step process is initiated by the phosphorylation of specific 
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Ser/Thr residues preceding a Pro and concluded with substrate catalysis by Pin1. 
Phosphorylation followed by Pin1 isomerization depicts one of many tightly regulated 
mechanisms for the well-known and controlled cellular process of mitosis
24
.  
To date, the literature describes studies that have used peptides containing one 
phosphorylation site to monitor Pin1 binding
8,23,49,56,94,95
. Using peptides containing two 
phosphorylation sites has been presented by Smet et al.
90
 to increase the binding affinity 
of Pin1 towards the peptide, but there is a decrease in isomerization activity
90
. In the 
present work, peptides comprising two different pThr-Pro motifs seem to interact with 
both domains of Pin1 because each domain has an affinity for a phosphate group. The 
peptides chosen are derived from human CDC25C protein, because it is a Pin1-
interacting protein that is naturally phosphorylated at multiple sites.  
This work utilizes peptides derived from the sequence of human CDC25C to 
investigate binding interactions with Pin1. Previous studies have shown that the binding 
of CDC25C to Pin1 requires the full length isomerase, as the individual protein domains 
decrease binding affinities. Some peptides have also shown no detectable binding to the 
PPIase domain of Pin
88,95,104,105
.  
1.10 Objectives and hypothesis 
The use of doubly-phosphorylated peptides to elucidate binding mechanisms by 
the protein Pin1 is a novel application. This study tests the hypothesis that doubly-
phosphorylated substrates bind more strongly to Pin1, if the phosphorylation sites are 
located on Thr residues preceding a Pro and when the recognition motifs are spaced apart 
in the peptide sequence. Many studies examined the substrate specificity of Pin1 using 
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singly phosphorylated peptides as well as peptides composed of shorter sequence 
lengths
90,104,106,107
. This approach will give insights into the binding of Pin1 to a specific 
and known interacting protein, human CDC25C. It also highlights binding affinities of 
the protein-peptide complexes, based on the number of peptide phosphorylation sites. 
This work was conducted to assess the overall global changes induced by 
phosphorylated-peptide binding to Pin1. The changes can give insights into binding 
locations of the peptides onto Pin1 and substrate affinities when bound. The goal of this 
project is to investigate the relationship between the peptidyl-prolyl isomerase Pin1 and 
how it binds to phosphorylated substrates and aims to determine whether a singly- 
phosphorylated substrate or a doubly-phosphorylated substrate has a lower dissociation 
constant and therefore a stronger binding affinity to the protein. This knowledge can lead 
to the generation or improvement of Pin1 inhibitors to decrease protein overexpression 
and its subsequent effects in cancer. Using peptides derived from the human protein 
CDC25C, known to promote the initiation of mitosis, changes to Pin1 have been assessed 
through the use of analytical ultracentrifugation (AUC) experiments, circular dichroism 
(CD) spectropolarimetry, nuclear magnetic resonance (NMR) and fluorescence 
polarization (FP) experiments. To further explore the binding interactions of Pin1, X-ray 
crystallography experiments were conducted however this was not chosen as one of the 
methods to pursue (See Appendix).  
Analytical ultracentrifugation is a technique that determines native state 
stoichiometries of proteins and protein subunits in solution. Conformational changes in 
macromolecules can also be identified by an optical detection system that measures the 
concentration gradient of the sample within a cell
108
. Protein sedimentation analysis 
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occurs in real-time. The experiments were conducted using sedimentation velocity to 
detect molecules tumbling together in solution and to determine molecular mass and 
shape
109
. These experiments addressed global changes in Pin1 upon phospho-peptide 
binding.  
The next technique used was circular dichroism spectropolarimetry.  This method 
observes peptide backbone amide bonds and aromatic side chains by measuring the 
differences between left and right handed circularly polarized light. Only chiral 
molecules will display differences in the directionality of polarized light passing through. 
The chromophores associated with protein amides can align into arrays and when 
aligned, the optical transitions produced are split into many transitions of different 
wavelengths and intensities
110
. Secondary structural elements have distinct CD spectra as 
a result of these transitions. Αlpha-helical secondary structures show a strong positive 
peak at 193 nm whereas β-sheets have a weaker positive peak at 195 nm. Both structural 
elements exhibit large negative curves between 208 and 250 nm in a CD spectrum
111
. The 
CD experiments conducted assessed changes in the secondary structure of Pin1 with the 
addition of peptides.  Protein and protein-peptide complexes were then tested by thermal 
melting, as secondary structural features can be denatured by high temperatures
112
. The 
stability of Pin1 and Pin1-peptide complexes was tested before moving onto binding 
studies. 
Following CD, nuclear magnetic resonance using 
1
H-
15
N heteronuclear single 
quantum coherence (HSQC) was used for peptide titration experiments. NMR affects 
atomic nuclei because they exhibit magnetism when subjected to a magnetic field
113,114
. 
A separate magnetic field that is orthogonal to the force applied by the magnet must be 
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applied to the atoms, with both fields having the same frequency
115
. This enables a 
magnetization when atomic nuclei are in thermal equilibrium
116
. Short pulses from a 
transversely oscillating magnetic field are applied to a sample to obtain free induction 
decay (FID) information. The FID is generated from the voltage induced by the 
absorption of energy
116
. 
Atomic nuclei generate resonant frequencies that are dependent on the location of 
each nucleus within a magnetic field.  The chemical environment surrounding a nucleus 
will affect which frequencies are absorbed
115
. The location of a nucleus, and therefore the 
corresponding resonant frequency, is critical information for the analysis of protein 
structure
116
. NMR gives insights into the Pin1 protein residues affected upon peptide 
addition. 
HSQC experiments relate nitrogen atoms and amide protons, characteristic of 19 
amino acid peptide bonds excluding proline. Each amide in the backbone of a protein, 
and side chains containing protons bound to nitrogen atoms, generate a peak in an HSQC 
spectrum
117
. Hydrogen nuclei have the largest gyromagnetic ratios and are the most 
sensitive atoms to use for NMR
118
.  The relaxation time associated with an experimental 
series is increased to obtain the most information from one experiment
115
. The Pin1 
backbone amino acids are located in an HSQC spectrum and changes in Pin1 can be seen 
in the spectra of Pin1 with increasing amounts of peptide.  
Fluorescence polarization is a technique that uses a fluorophore to detect potential 
interactions in solution. A ligand is labeled with a fluorescent marker and once the ligand 
is excited it will emit light at a given wavelength. This light can be easily detected if 
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mobile in solution, but when the ligand is bound by another molecule its mobility will 
decrease. An increased amount of emitted light will be polarized upon binding, compared 
to that of the free ligand, indicative of a protein interaction
119
. The polarization of 
fluorescent light can be measured quantitatively to determine dissociation constants for 
Pin1-peptide complexes.  
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2. Materials and Methods 
2.1 Expression and purification of recombinant Pin1 proteins 
2.1.1 Hexa-histidine tagged proteins 
To generate recombinant proteins, histidine-tagged wild type Pin1 (His-Pin1), 
Arg14Ala Pin1 (R14A Pin1) and Arg14Ala Cys113Asp Pin1 (R14A C113D Pin1) 
constructs (Figure 4) were cloned into pProEX-HTA plasmids and expressed in BL21 
DE3 Escherichia coli (E.coli) cells. These plasmids were a generous gift from Dr. Brian 
Shilton. Colonies were picked and grown to an optical density (OD)600 of ~ 0.6 in Luria-
Bertani medium supplemented with 100 μg/mL ampicillin (Roche) at 37 ºC with shaking 
at 200 rpm.  Once the desired OD600 was reached, protein expression was induced with 
0.6 mM isopropylthio-α-ᴅ-β-galactoside (IPTG) (Roche) for three hours at 37 ºC. 
Bacteria were pelleted by centrifugation at 4420 x g for 15 minutes (mins) and 
resuspended in a 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) buffer 
comprising 10 mM HEPES, 100 mM NaCl and 5 mM NaN3, pH 7.4 with protease 
inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/mL pepstatin A and 10 
μg/mL leupeptin) (Sigma). The cells were lysed using an EmulsiFlex-C3 pressure 
homogenizer (Avestin) at 15,000 psi and the cell debris was pelleted by centrifugation at 
23 300 x g for 20 mins. The soluble fraction of lysate was loaded onto a 5 mL HisTrap 
HP nickel sepharose affinity column (GE Healthcare Life Sciences). The column was 
washed with 20 column volumes of HEPES buffer with an additional 10 mM imidazole, 
followed by 10 column volumes of HEPES buffer with 50 mM imidazole and all washes 
were collected.  Histidine6-tagged Pin1 (His-Pin1) constructs were eluted using HEPES 
buffer with 500 mM imidazole in 15 1.5 mL fractions. Eluted fractions were monitored at 
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an absorbance (A) wavelength of 280 nm, using an ÄKTA FPLC system (GE Healthcare 
Life Sciences). 
The protein concentration of the eluted fractions was determined by A280, after 
pooling the fractions containing His-Pin1 protein, and analyzed by 15% SDS-PAGE gels 
using SDS-PAGE buffer (192 mM glycine (Bioshop), 25 mM Tris-base (Bioshop), 0.1% 
SDS (Bioshop) at a constant voltage of 150 V for 75 mins. A prestained BLUEye 
molecular weight marker (FroggaBio) was used for reference. Protein purity was assessed 
by staining with Coomassie R-250 Brilliant Blue (Bio-Rad). Tobacco Etch Virus (TEV) 
protease was added to the protein at a molar ratio of 1:25, along with 5 mM DTT and 1 
mM EDTA. This solution was rotated at room temperature for 5 hours, followed by the 
addition of a second aliquot of TEV, DTT and EDTA.  After rotation at room 
temperature overnight, the solution was spun down at 3724 x g to remove any precipitant 
and then dialyzed against 1 L of HEPES buffer for at least 6 hours at 4 ºC. The solution 
was then loaded onto a 5 mL HisTrap column using HEPES buffer containing 10 mM 
imidazole, where the His-TEV would remain bound to the column while the un-tagged 
Pin1 protein would come off in the flow through. The flow through was then collected 
and purified wild type His-Pin1 was concentrated and dialyzed into 2x HEPES buffered 
saline (HBS) (280 mM NaCl, 50 mM HEPES, 12 mM Dextrose, 10 mM KCl, 1.5 mM 
Na2HPO4,  pH 7.0) at 4 °C for 16 hours to remove imidazole. Purified R14A Pin1 and 
R14A C113D Pin1 were concentrated to greater than 18 mg/mL using an Amicon Ultra 
centrifugal filter tube (Millipore) and dialyzed into crystallization buffer (10 mM HEPES, 
100 mM NaCl, 5  mM NaN3, 5 mM DTT and 1 mM EDTA), containing 20% glycerol 
(Caledon), at 4 °C for 16 hours to remove imidazole.  Where proteins were required for 
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different experimental procedures, the proteins were dialyzed against their respective 
buffers as indicated elsewhere. All protein concentrations were determined using the 
Bradford Protein Assay (Bio-Rad), before being flash frozen and stored at -80 °C.  
2.1.2 GST tagged proteins  
For NMR experiments, wild type Pin1 protein was expressed with a GST-tag 
(Figure 4) from a pGEX-KG vector in BL21 DE3 E. coli cells, courtesy of Dr. Melanie 
Bailey. Colonies were picked and grown to an optical density (OD)600 of ~ 0.9 in M9 
media supplemented with 1.0 g/L of 99% 
15
NH4Cl (Cambridge Isotope Laboratories)  
and 100 μg/mL ampicillin (Roche) at 37 ºC, shaking at 250 rpm.  Once the desired OD600 
was reached, protein expression was induced with 0.6 mM IPTG (Roche) overnight at 16 
ºC. Bacteria were pelleted by centrifugation at 4420 x g for 15 mins and resuspended in 
cold phosphate buffered saline (PBS), pH 7.5, containing protease inhibitors (1 mM 
PMSF, 10 μg/mL pepstatin A and 10 μg/mL leupeptin) (Sigma). The cells were lysed 
using a pressure homogenizer (Avestin) at 15, 000 psi. Triton X-100 (Sigma) was added 
to 1% of the total volume and the solution was rotated for 15 min at 4°C. The cell debris 
was pelleted by centrifugation at 23 300 x g for 20 mins and the supernatant was 
incubated with glutathione cross-linked agarose beads (Sigma) while rotating for one 
hour at 4 °C. The beads were washed with two column volumes of cold PBS and then the 
protein was eluted in 12 fractions of 1.5 mL each, with 10 mM reduced glutathione 
(Sigma) in PBS, pH 7.5. Aliquots of washes and eluates were analyzed by visualization 
on a 15% SDS-PAG.   
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Figure 4   
Figure 4 Purified recombinant Pin1 protein construct sequences. 
His-Pin1 constructs contain an N-terminal hexa-histidine tag and a tobacco etch virus 
(TEV) cleavage recognition sequence for ease of purification and then to remove the His-
tag. Three His-Pin1 proteins were purified: wild type full length Pin1 (His-Pin1), His-
Arg14Ala Pin1 (R14A Pin1) and His-Arg14Ala Cys113Asp Pin1 (R14A C113D Pin1). 
R14A Pin1 is the full length Pin1 protein, with a deletion of the five N-terminal amino 
acids and a single residue substitution at residue 14 in the WW domain, to increase 
protein stability for crystallization. R14A C113D Pin1 is the R14A Pin1 sequence with an 
additional single residue substitution at residue 113 in the PPIase domain. A GST-Pin1 
fusion protein was also generated. This construct contains an N-terminal GST protein 
sequence attached to a TEV cleavage recognition sequence and wild type full length 
Pin1.  
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TEV protease was added to proteins in a 1:20 ratio of TEV to protein, to remove 
the GST-fusion tag. This incubation was conducted twice, for 5 hours and then overnight, 
at room temperature with constant rotation. An overnight dialysis into TEV cleavage 
buffer (50 mM Tris-HCl, 10 mM EDTA, 5 mM NaN3, 20 mM β-mercaptoethanol, pH 
8.0) at 4 °C was performed, preceding a TEV cleavage reaction where TEV and protein 
were mixed with 5 mM DTT and 1 mM EDTA.  Next the sample was spun down at 3724 
x g to remove any precipitation and followed by a buffer exchange, using a 10 mL stirred 
cell (Millipore) connected to a Nitrogen gas pressure supply, into a phosphate buffer 
containing 10 mM monobasic sodium phosphate, 5 mM NaN3, 20 mM β-
mercaptoethanol, 300 mM NaCl and 15% glycerol (pH 6.5).  The protein was loaded 
onto a 120 mL HiPrep 16/60 Sephacryl S-100 High Resolution gel filtration column (GE 
Healthcare) equilibrated with the final NMR phosphate buffer (50 mM phosphate buffer, 
100 mM Na2SO4, 1 mM DTT, 5 mM EDTA, 5 mM NaN3,  pH 6.6). Proteins were eluted 
from the column and collected into a total of 95 0.5 mL fractions. Aliquots of fractions 
were analyzed on 15% SDS-PAGE gels and stained with Coomassie R-250 Brilliant Blue 
(Bio-Rad) to assess purity. Fractions containing the appropriate pure protein were pooled 
and concentrated using a 15 mL Amicon centrifuge filter (3000 MWCO) (Millipore). 
Protein concentrations were determined using the Bradford Protein Assay (Bio-Rad). 
Protein purity and integrity was assessed by SDS-PAGE and matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry, while protein concentration was 
confirmed through amino acid analysis (SickKids Proteomics, Analytics, Robotics & 
Chemical Biology Centre (SPARC), Toronto). The final volume and concentration of the 
15
N-labeled Pin1 NMR samples were 650 μL and 322 μM respectively, following the 
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addition of 10% D2O to provide the field frequency lock, 100 μM 2,2-dimethyl-2-
silapentane-5-sulfonic acid (DSS) as an internal standard and 1.5 mM imidazole (pH 8.0)  
to act as an internal pH monitor throughout the experiments.  
2.2 Human CDC25C peptides 
All peptides derived from human CDC25C were synthesized by EZBiolab 
(Carmel, Indiana). Peptides were prepared to 95.1 – 96.6% purity, as determined by 
HPLC analysis conducted by EZBiolab. Peptide sequences contained 32 amino acids and 
were as follows: CPDVPRTPVGKFLGDSANLSILSGGTPKRSLD, 
CPDVPRpTPVGKFLGDSANLSILSGGTPKRSLD, 
CPDVPRTPVGKFLGDSANLSILSGGpTPKRSLD and 
CPDVPRpTPVGKFLGDSANLSILSGGpTPKRSLD (referred to as 0xP, 1xP #1, 1xP #2 
and 2xP respectively). Peptides were resuspended in the buffers mentioned for each 
experiment. Any peptide modifications were confirmed by MALDI Mass Spectrometry 
(MALDI Mass Spectrometry Facility, one of the facilities within the London Regional 
Proteomics Centre, Ontario). 
2.3 Peptidyl-prolyl isomerization activity assays 
Peptidyl-prolyl isomerase activity for each of the purified Pin1 proteins was 
determined with a spectrophotometric assay using a Cary-100 spectrophotometer at 0 °C.  
Enzymatic assays were performed in Assay buffer (50 mM HEPES, 100 mM NaCl, 
5 mM NaN3, pH 7.4), as described in Behrsin, et al. 2007 and Duncan, et al. 2011
77,79
. 
The protein substrate Succinyl-AEPF-pNitroaniline (Suc-AEPF-pNA) (Bachem) was 
dissolved in trifluoroethanol with 0.3 M LiCl, to maximize the amount cis-proline, 
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producing a stock concentration of 20 mM. The chymotrypsin (Type II, Sigma) had a 
concentration of 50 mg/mL, dissolved in 1 mM HCl.  Reactions were performed with 
increasing concentrations of substrate, added to assay buffer, to a total sample volume of 
2 mL. This was incubated for at least 30 seconds before adding a final concentration of 
1.25 mg/mL chymotrypsin to enable the depletion of trans-proline peptide. The rate of 
chemical isomerization was measured as an absorbance over time until the slope became 
linear. 0.5 µM from a 20 µM stock of Pin1 was then added to the sample and the rate of 
both the Pin1-catalyzed as well as the un-catalyzed isomerization was measured. The run 
continued until all of the protein substrate was consumed and the absorbance plot 
displayed a slope of zero.   
Absorbance measurements were made at different wavelengths, depending on the 
increasing substrate concentration, with an extinction coefficient (ε) for pNA of 6026 cm-
1
 M
-1 
at 405 nm, 3680 cm
−1 
M
−1
 at 430 nm and 1380 cm
−1 
M
−1
 at 445 nm, to stay within 
the responsive range of the spectrophotometer. For each assay, the rate of un-catalyzed 
chemical isomerization was subtracted from the total isomerization rate, of the catalyzed 
and un-catalyzed reactions, to determine the Pin1-catalyzed cis-trans isomerization. The 
rate against the substrate concentration was plotted to determine a kcat / Km value, by 
fitting the values to a modified Michaelis-Menten equation for competitive inhibition, 
where only the linear region of the curve is used due to low substrate concentrations. The 
equation used is:   
Rate = (kcat / Km) * [S] [E]T  
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where [S] is the substrate concentration, [E]T is the enzyme concentration, the 
slope of the line gives the kcat / Km * [E]T, and the kcat / Km is determined by dividing the 
slope by the final Pin1 protein concentration in the assay.  
2.4 Amino acid analysis 
Samples of soluble Pin1 protein, obtained from the GST-Pin1 construct, and 0xP 
and 2xP peptides were sent for quantitative amino acid analysis to the Peter Gilgan 
Centre for Research & Learning at the Hospital for Sick Children (SPARC Biocenter, 
Toronto). The protein samples were quantified by Bradford and Guanidine-hydrochloride 
assays, comparing the protein to BSA standards or measuring an absorbance reading at 
280 nm, respectively. The protein and peptide samples were all to be used for NMR 
experiments. 
2.5 Analytical ultracentrifugation 
A Beckman Optima XL-A analytical ultracentrifuge (Biomolecular Interactions 
and Conformations Facility, University of Western Ontario) was used to perform these 
experiments, with an An60Ti rotor. All protein and peptide samples used were dialyzed 
into 2x HBS buffer and spun down at 13,000 rpm to remove aggregates before AUC data 
collection. The solvent densities used were calculated from published tables. The protein 
sample partial specific volumes were calculated based on their amino acid sequences
120
. 
2.5.1 Sedimentation velocity 
Two sector cells with quartz windows were used to complete the sedimentation 
velocity experiments. Data were collected for the wild type Pin1 protein at a 
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concentration of 15 µM and a speed of 45,000 rpm. Scans of all cells were taken every 
ten minutes, and averaged over three readings.  
Data analysis was performed using the Origin 6.1 software (Microcal) and 
SVEDBERG
121
. Sedimentation coefficients (sw) were calculated using the method of 
sedimentation time derivative. Values were averaged from three separate sedimentation 
velocity runs and were then corrected to standard values for experiments conducted at 20 
ᴼC and in pure water (sw20,w). The frictional coefficient (ƒ) of 1.399153 used in the 
experiments was calculated from the measured sw20,w according to the following 
equation: 
 ƒ = [M * [(1- ṽρ)] / (N * sw20,w) 
where M is the molecular mass of the protein, ṽ is the partial specific volume of 
the protein, ρ is the density of the buffer and N is Avogadro’s number. 
2.6 Circular dichroism spectropolarimetry 
Circular dichroism experiments were conducted using a Jasco J-810 
spectropolarimeter with a Peltier temperature controlled system (Biomolecular 
Interactions and Conformations Facility, University of Western Ontario). A cell with a 
path length of 1 mm was used after Pin1 protein, obtained from the GST-Pin1 construct, 
and protein-peptide solutions were dialyzed into a 10 mM sodium phosphate buffer (100 
mM Na2SO4, 5 mM NaN3, 5 mM EDTA and 1 mM DTT, pH 6.6) and spun down to 
remove precipitants.  
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CD spectra were collected for recombinant Pin1 proteins used for NMR 
experiments. The protein concentration was 48 µM and the CD experiments were 
conducted at 25 ᴼC, scanning from 180 - 250 nm in 1 nm steps, and at a scanning speed 
of 50 nm/min. When a protein-peptide sample was measured, either 0xP or 2xP peptide 
was added at two equivalents of the protein. The ellipticity values were generated from 
averaging readings taken between one and four seconds at each wavelength and then 
averaged over ten separate scans of each sample.  The software supplied by Jasco was 
used for data collection, and then plotted using Excel (Microsoft). The observed 
ellipticity values, given in millidegrees, were converted to mean residue ellipticity (MRE) 
values in degree*cm
2
*dmol
-1
 as the units. This conversion is achieved using the equation: 
 ϴmre = (ϴobs * MRW) / (10 *l * c)  
where ϴmre is the mean residue ellipticity, ϴobs is the observed ellipticity value in 
millidegrees, MRW is the mean residue weight which is calculated based on the 
molecular weight of the protein divided by the number of residues within the protein, l is 
the path length of the CD cuvette in centimeters and c is the protein concentration in 
g*mL
-1
. 
Recombinant Pin1 was also analyzed with melting curves. The protein, at a 
concentration of 48 µM, was melted by increasing the temperature at a rate of 
1ᴼC/minute using the Peltier system. The curve ranged from 20 to 90 ᴼC. When a protein-
peptide sample was measured, either 0xP or 2xP peptide was added at two equivalents of 
the protein.  Ellipticity values were obtained by averaging the readings taken over an 
eight second time frame at 228 nm. The observed ellipticity values, given in millidegrees, 
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were converted to mean residue ellipticity values in degree*cm
2
*dmol
-1
 as the units. The 
resulting curves were plotted in Excel (Microsoft). 
2.7 Pin1-peptide NMR titrations 
All 
1
H-
15
N HSQC NMR experiments were conducted on a Varian Inova 600 MHz 
spectrometer with pulse field gradient triple resonance probes, at 25 ᴼC. 0xP and 2xP 
peptides were unlabeled and prepared as 2 mM stock solutions in NMR buffer. The 
peptides underwent an overnight dialysis at 4 ᴼC to ensure buffer compatibility with the 
protein solutions. The concentration of the peptide solutions were determined by amino 
acid analysis (SPARC Biocentre, Toronto).  The peptides were titrated separately into 
solutions of uniformly labeled 
15
N- Pin1 (322 μM) in increments of 0.25 molar 
equivalents, until a final peptide concentration of 2 molar equivalents was reached. The 
sample was mixed at each addition and equilibrated in the magnet for a minimum of 10 
mins prior to data acquisition. 
1
H and 
15
N chemical shift assignments for Pin1 were 
transferred from Jacobs et al., BMRB 5305
122
. Chemical shift perturbations observed in 
the 
1
H-
15
N HSQC spectra between the free and complexed states of the protein were 
quantified using the equation: 
ΣΔδ = 0.5(|Δδ(1H)|) + 0.125 (|Δδ(15N)|) 
where Δδ is the chemical shift change. 
The combined chemical shift changes were calculated for the entire Pin1 protein, based 
on the above equation from Duncan et al., 2011
79
. The chemical shift changes observed, 
were mapped to Pin1 using the coordinates from the 1PIN crystal structure.  
34 
` 
2.8 Fluorescence polarization experiments 
All peptides were fluorescently labeled with NHS-Fluorescein (Pierce 
Biotechnology, Inc.) following the manufacturer’s protocol. Peptides were dissolved at 
150 µM in 50 mM borate buffer, pH 8.5.  Briefly, NHS-Fluorescein (1 mg in 100 µL 
DMSO) was added in a 15-fold molar excess to the peptide. The reaction was incubated 
at room temperature for one hour and excess label was consumed with a 30-fold molar 
excess of ethanolamine, pH 8.5. Peptides were dialyzed into 2x HBS (280 mM NaCl, 50 
mM HEPES, 12 mM Dextrose, 10 mM KCl, 1.5 mM Na2HPO4,  pH 7.0) and labeling 
was confirmed using MALDI Mass Spectrometry (MALDI Mass Spectrometry Facility, 
part of the London Regional Proteomics Centre, Ontario). Peptides were stored in the 
dark during all of the labeling and subsequent steps.  
Fluorescence polarization assays were read using an Envision 2103 multi-plate 
reader (PerkinElmer). Optimal dilutions for each peptide were determined with the use of 
a reference peptide to give off a fluorescent signal within range of the detector. These 
dilutions were confirmed and used in all future experimentation. Individual reactions 
were conducted in duplicate, in a 35 μL volume, using a 384-well black plate (Corning). 
The protein was serially diluted from a concentration of 800 μM and 30 μL of protein 
was added to each well. Finally, 5 μL of 150 μM peptide was added to each well before a 
1 min incubation time with agitation (500 rpm) at room temperature. Before reading the 
assay, the plate was spun for 1 min at 100 x g and incubated for an additional 10 mins at 
room temperature. Analysis was performed using Prism 5 (GraphPad Software, Inc.) by 
subtracting the buffer sample polarization and the polarization associated with non-
specific binding between the protein and the fluorescent tag. The data was then fit to a 
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non-linear regression for one-site, specific binding as a function of protein concentration. 
The equation used for data fitting was as follows:  
y = Bmax * x / (Kd + x) 
where Bmax is the maximum specific binding value in fluorescence polarization 
units and Kd is the dissociation constant (µM). 
2.9 Pin1 crystallization 
Arg14Ala Pin1 and Arg14Ala Cys113Asp Pin1 constructs were crystallized by 
hanging drop vapour diffusion over three days in 2.3 and 2.4 M ammonium sulphate, 1% 
(v/v) polyethylene glycol 400 (PEG400) and 100 mM HEPES at 5 °C, pH 7.8.   
2.10 X-ray crystallography data collection and structure 
refinement 
Electron diffraction data was collected using a laboratory source in the 
Macromolecular Crystallography Facility (part of the London Regional Proteomics 
Centre, Ontario). The data was processed using IMOSFLM
123
 and Scala
124
. Structure 
solution and refinement was done by molecular replacement in PHENIX
125
 using the 
PDB file 2ITK
107
, after ligand removal, as the starting model for the Arg14Ala 
Cys113Asp Pin1 structure, and the PDB file 4QIB
126
 as the model for the refinement.  
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3. Results 
3.1 Protein purification and activity 
Recombinant Pin1 proteins were purified in order to examine binding interactions 
between Pin1 and CDC25C-derived peptides. Various His-Pin1 recombinant protein 
constructs were purified by affinity purification using nickel columns where His-tagged 
proteins were eluted with imidazole. To remove the His-tags, eluted proteins were 
incubated with TEV using a reducing agent to stabilize protease activity.  Since the TEV 
also contains a His-tag, the cleaved Pin1 was separated from His-TEV and any un-
cleaved His-Pin1 by passing the reaction mixture over another nickel column (Figure 
5A). Following the removal of the tags using TEV protease, the proteins were dialyzed 
into their final storage buffers. A wild type Pin1 construct was also fused to a GST-tag 
(GST-Pin1) and purified first using affinity chromatography, then TEV cleavage and a 
gel filtration step (not shown). None of the proteins used in the experiments described in 
the following sections contained tags.  
To determine the isomerization activity of the purified proteins, a peptidyl-prolyl 
isomerization activity assay was performed using Suc-AEPF-pNA as a substrate, 
containing a para-Nitroaniline (pNA) on the C-terminus. The substrate peptide is added 
to the assay buffer to determine a baseline absorbance at 405 nm. Chymotrypsin is then 
added to remove all of the trans isomers of the substrate, releasing pNA which can be 
detected spectrophotometrically.  Following the trans-peptide cleavage, the absorbance 
curve flattens and generates a positive slope, representing the un-catalyzed chemical 
isomerization rate of the substrate. From there, recombinant Pin1 is added to the reaction 
mixture and the absorbance curve shows a linear slope while the peptide is still in excess. 
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This slope depicts the catalyzed isomerization rate generated by Pin1 in addition to the 
un-catalyzed chemical isomerization rate. The substrate continues to be depleted by Pin1 
as well as chymotrypsin, until it has all been utilized. The absorbance value at the point 
of Pin1 addition is subtracted from the absorbance value at the end of the curve to 
calculate the concentration of peptide within the system when protein is added. The slope 
of the un-catalyzed isomerization is subtracted from the slope of both the catalyzed and 
un-catalyzed isomerizations, to determine the enzymatic peptidyl-prolyl isomerization 
rate of Pin1 (Figure 6). This process is repeated to calculate the isomerization rate of 
Pin1 using increasing substrate concentrations and the data is graphed as the Pin1 
isomerization rate, in mM/s units, as a function of cis-peptide concentration. The linear 
slope from this plot, in s
-1
 units, is divided by the concentration of protein in the assay to 
obtain a specificity constant  or kcat /Km value in mM
-1 
* s
-1 
units (Figure 5B).  
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Figure 5 (A-B) 
  
Figure 5 Purified recombinant Pin1 protein and peptidyl-prolyl isomerase activity.  
(A) SDS-PAGE of purified wild type His-Pin1 protein. Pin1 is approximately 18 kDa and the His-
TEV protein runs at a higher molecular weight on a polyacrylamide gel, depicted by the band 
labeled TEV in the figure. Other His-Pin1 constructs were purified using a similar affinity 
purification protocol (gels not shown). 
(B) Peptidyl-prolyl isomerase assay analysis of a wild type Pin1 construct. The assay is conducted 
with increasing amounts of substrate to determine an isomerization rate. The kcat / Km value is 
representative of the activity of the Pin1 enzyme. 
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Figure 6 
  
Figure 6 Pin1 peptidyl-prolyl isomerization assay sample curve. 
The peptidyl-prolyl isomerization activity of purified Pin1 proteins is determined 
spectrophotometrically. The peptide Succinyl-AEPF-pNitroaniline (Suc-AEPF-pNA) is used as a Pin1 
substrate in the assay, and when released the pNA, located on the C-terminus of the peptide, can be 
detected spectrophotometrically.  The substrate peptide is added to the assay buffer to determine a 
baseline absorbance at 405 nm (Abs start). Chymotrypsin is then added, seen by the rapid absorbance 
increase, to remove all of the trans isomers of the substrate. Following the trans-peptide cleavage, the 
absorbance curve flattens and generates a positive slope, representing the un-catalyzed chemical 
isomerization rate of the substrate (Abs isom).  Recombinant Pin1 is added to the reaction and the 
initial rate of the absorbance curve is measured by fitting a line to the curve, immediately after the point 
at which Pin1 is added (Abs total isom). This slope represents the catalyzed isomerization rate 
generated by Pin1 in addition to the un-catalyzed chemical isomerization rate. The absorbance value 
upon Pin1 addition is subtracted from the final absorbance value of the curve to calculate the 
concentration of peptide when protein is added. The inset shows an expanded portion of the assay 
curve. Abs isom, the slope of the purple region of the curve, is subtracted from Abs total isom, the 
slope of the blue region of the curve, to determine the peptidyl-prolyl isomerization rate of Pin1. This 
process is repeated to calculate the isomerization rate of Pin1 using increasing substrate concentrations. 
The data is graphed as the Pin1 isomerization rate (s
-1
) when divided by the Pin1 concentration, as a 
function of cis-peptide concentration (mM).   
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3.2 Peptide addition to Pin1 does not cause global 
conformational changes 
Peptides for this study were synthesized with sequences designed from a known 
Pin1 substrate, CDC25C (Table 1). The peptides depict a portion of the CDC25C protein 
where there are two phospho-threonine sites in the sequence, 19 amino acids apart, at 
residues 48 and 67
127
. The non-phosphorylated (0xP), both of the singly-phosphorylated 
(1xP #1 and 1xP #2) and the doubly-phosphorylated (2xP) CDC25C-derived peptides 
were used for these experiments (Figure 7). Results were generated through the use of 
analytical ultracentrifugation, a technique that can determine native state stoichiometries 
of protein subunits and detect conformational changes in macromolecules. The 
ultracentrifuge contains an optical detection system that can measure the concentration 
gradient of the enclosed sample within a centrifuge cell
108
. Sedimentation analysis is 
completed in solution while observing real-time changes, minimizing the risk of protein 
interactions with resins or other surfaces. The experiments were conducted using 
sedimentation velocity to detect molecules tumbling together in solution. This technique 
is used to determine molecular mass and shape in solution when applying a centrifugal 
force. At given time intervals, scans at various radial distances measure the concentration 
of a solution based on an absorbance at 280 nm. The rate at which molecules move and 
sedimentation occurs is measured over time
108,109
. 
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Table 1 
Table 1 Cdc25 derived peptides synthesized to test binding affinities to Pin1 protein 
in vitro.  
The phosphorylation sites all occur on Thr residues and are depicted in red. 
 
Human Cdc25 peptide sequence Phosphorylation 
Site 
Shorthand 
Title 
CPDVPRTPVGKFLGDSANLSILSGGTPKRSLD None  0xP 
CPDVPRpTPVGKFLGDSANLSILSGGTPKRSLD Site #1 1xP #1 
CPDVPRTPVGKFLGDSANLSILSGGpTPKRSLD Site #2 1xP #2 
CPDVPRpTPVGKFLGDSANLSILSGGpTPKRSLD Sites  #1 and #2 2xP 
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Data was collected using wild type Pin1 and each of the CDC25C-derived 
peptides, in triplicate, at a rotor speed of 45,000 rpm. After each experiment, the values 
of sedimentation coefficients observed (sw) were calculated, averaged and corrected for 
temperature effects as well as buffer effects (sw20,w) . A frictional ratio of f/fo= 1.399153 
was used for each experiment. Pin1 was mixed with each peptide at molar ratios of 1:1 
and 1:2 equivalents of protein to peptide.  The experiments resulted in a consistent 
molecular weight and sedimentation coefficient for the control reaction of Pin1 alone, 
within error (Figure 7, first plot in each panel).  Each graph shows the sedimentation 
coefficient distribution (c(s)), in 1/Svedbergs (1/S), of each protein or complex as a 
function of sedimentation coefficient, in Svedbergs (S). When mixed with the non-
phosphorylated peptide, the Pin1-peptide complex gives a narrowed peak and a slight 
decrease in sedimentation coefficient at a ratio of 1:1, but this value increases back to 
original levels at a ratio of 1:2, whereas the peak stays narrow (Figure 7A). The Pin1-
1xP #1 complex displays an increasing sedimentation coefficient as the amount of 
peptide in the sample is increased (Figure 7B). The peaks however exhibit the same 
trend as that observed for 0xP, a narrowing when peptide is added. The singly-
phosphorylated site #2 peptide set of experiments generated the largest sedimentation 
coefficients. The coefficient decreases when peptide is added to Pin1 and then increases 
when more peptide is added. The peaks observed for Pin1 and the 1:1 ratio of protein to 
peptide are similar in width, but the peak narrows with an increase in peptide (Figure 
7C). The sedimentation coefficients and narrow peaks for the 2xP peptide set of 
experiments display no change when peptide is added to the protein (Figure 7D). This is 
indicative of a folded, homogeneous sample in solution. The sedimentation coefficients 
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of all the protein-peptide complexes fall within range of the control protein alone 
samples, where the sw20,w values are 2.05 – 2.25 S. It is important to note that the 
molecular weights (M) are calculated based on sedimentation coefficients, where sw is 
approximately M
2/3
, indicating that the masses are subjected to a larger standard error
109
. 
Taken together, the changes occurring when the CDC25C-derived peptides are mixed 
with wild type Pin1 are minimal and there are therefore no large global conformational 
changes seen with peptide addition. 
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Figure 7 
sw (20,w) = 2.186S 
MW = 23.138 kDa  
 
sw (20,w) = 2.224S 
MW = 23.754 kDa  
 
sw (20,w) = 2.130S 
MW = 22.255 kDa  
 
sw (20,w) = 2.045S 
MW = 20.932 kDa  
 
sw (20,w) = 2.200S 
MW = 23.364 kDa  
sw (20,w) = 2.189S 
MW = 23.186 kDa  
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Figure 7 Caption 
  
Figure 7 Sedimentation velocity experiments of Pin1 with CDC25C-derived 
peptides. 
The non-phosphorylated 0xP peptide (A), singly-phosphorylated peptides at site #1 
(B) and site #2 (C) and the doubly-phosphorylated 2xP peptide (D) were each mixed 
with Pin1 (15 µM) in either a 1:1 or 1:2 ratio of protein to peptide. The sedimentation 
velocity experiments were conducted at a speed of 45,000 rpm and scans of all cells 
were taken every ten minutes, and averaged over three readings. Sedimentation 
coefficients (sw) were calculated using the method of sedimentation time derivative. 
Values were averaged from three separate sedimentation velocity runs and were then 
corrected to standard values for experiments conducted at 20 ᴼC and in pure water (sw 
(20,w)). The frictional coefficient (ƒ) used in the analysis was 1.399153. Protein alone 
was used as a control in each experiment and is shown in the first graph of each panel.  
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3.3 Pin1 stability does not change with peptide addition 
Pin1 protein alone, as well as protein with either 0xP or 2xP peptide were 
examined using circular dichroism. CD spectropolarimetry is a technique used to observe 
peptide backbone amide bonds and aromatic side chains by measuring the differences 
between left and right handed circularly polarized light in chiral molecules
110
. Protein 
amides have chromophores that can align into arrays, and when aligned, the optical 
transitions produced can be split into many transitions with different wavelengths and 
intensities associated to each. Secondary structural elements have distinct CD spectra as a 
result of these transitions
111
. The protein and protein-peptide complexes in the present 
study show similar α-helical and β-sheet secondary structures, defined by the large 
negative curves between 212 and 250 nm (Figure 8A). The positive trends occurring 
from 180 to 208 nm which depict α-helices with a strong peak at 193 nm and β-sheets 
with a weaker peak at 195 nm
111
, indicate that there may be some variation in secondary 
structure between the samples, because none of the plots have the same mean residue 
ellipticity values at each wavelength (not shown).  
The stability of each complex was then tested by thermal melting, as secondary 
structural features can be denatured by high temperatures
112
. CD can be used to follow 
protein and protein-peptide stability by examining a specific wavelength and the spectral 
changes occurring in response to temperature. The melting temperatures for Pin1 and the 
protein-peptide complexes remain the same, starting to melt at 50 ᴼC and unfolding until 
60 ᴼC when the protein is denatured (Figure 8B).  There are visible transitions in the 
thermal denaturation profiles due to the loss of secondary structural elements. Observing 
the same thermal melting profiles for each of the samples is indicative of a constant 
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stability. The CDC25C-derived peptides therefore do not seem to have any major effect 
on Pin1 protein stability in solution. 
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Figure 8 Secondary structure and thermal stability analysis of Pin1 and Pin1-peptide 
complexes. 
(A) Circular dichroism spectropolarimetry analysis of Pin1 and Pin1 with either 0xP or 2xP 
peptide. The spectra were collected from 260 to 180 nm in a 10 mM sodium phosphate buffer (pH 
6.6) with 100 mM Na2SO4, 5 mM NaN3, 5 mM EDTA and 1 mM DTT at 25 ᴼC, at a rate of 50 
nm/min. The depicted spectra are the average of 10 accumulations, corrected for buffer effects 
based on protein concentration and path length. All spectra were collected in a 1.0 mm cuvette. 
The x-axis of the plot shows the wavelength while the y-axis of the plot shows mean residue 
ellipticity (MRE). (B) Thermal denaturation curves were constructed by monitoring changes in 
ellipticity at 228 nm from 20 to 90 ᴼC in the above sodium phosphate buffer, at a rate of 1 ᴼC/min. 
The overlaid spectra are corrected for buffer effects and take protein concentration and path length 
into account. The x-axis of the plot shows temperature while the y-axis of the plot shows mean 
residue ellipticity (MRE). 
 Figure 8 
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3.4 Pin1 interacts with a phosphorylated CDC25C peptide 
Pin1 protein as well as the Pin1-0xP and the Pin1-2xP complexes were tested for 
(not shown), binding interactions through the use of 
1
H-
15
N HSQC NMR titration 
experiments. NMR has been used as a tool to investigate protein structures
128
 and is 
based on the premise that atomic nuclei exhibit magnetism when subjected to a magnetic 
field
113,114
. Resonance occurs when nuclei are re-oriented from their natural equilibrium 
states by the magnetic field applied. For NMR, a torque or separate magnetic field that is 
orthogonal to the torque applied by the magnet must be applied to the atoms with both 
fields having the same frequency
115
. The strength of the second magnetic field is 
proportional to the resonant frequency of a sample, and determines the amount of 
magnetization when atomic nuclei are in thermal equilibrium
116
. Short pulses of a 
transversely oscillating field are applied to a sample in order to obtain free induction 
decay information, based on the voltage induced by the absorption of energy. The 
oscillations are visible in the time domain of the FID, and when a Fourier transform is 
performed on the data, a spectrum is generated in the frequency domain
116
.  
The resonant frequencies of the atomic nuclei within a sample are dependent on 
the location of each nucleus within the magnetic field. The location of a nucleus, and 
therefore the corresponding resonant frequency, is the critical information gathered when 
a sample is subjected to a torque within a field
116
. The chemical environment, as well as 
other nuclei surrounding a particular nucleus, will affect which frequencies are 
absorbed
115
. Distance measurements between the nuclei in a sample are useful for the 
determination of a protein structure.  
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HSQC experiments relate nitrogen atoms and amide protons, which are 
characteristic of all amino acid peptide bonds excluding proline. Each amide in the 
backbone of a protein, and side chains containing protons bound to nitrogen atoms, 
generate a peak in an HSQC spectrum
117
. Hydrogen nuclei have the largest gyromagnetic 
ratios and are therefore the most sensitive atoms to use for NMR
118
.  In an HSQC 
experiment, the hydrogen atom signal is detected in the first dimension, which is directly 
measured, and the chemical shift of 
15
N is indirectly measured throughout the series of 
one experiment. The relaxation time associated with an experimental series is increased 
to obtain the most information out of a single experiment
115
. 
NMR spectroscopy studies were conducted at 25 ᴼC and the buffers and 
experimental conditions were modeled based on the paper by Duncan et al.
79
. The 
doubly-phosphorylated 2xP peptide was titrated into solutions of uniformly, isotopically 
labeled 
15
N- wild type Pin1, until a final peptide concentration of 2 molar equivalents was 
reached. 
1
H and 
15
N chemical shift assignments for Pin1 were transferred from Jacobs et 
al., BMRB 5305
122
. 
Chemical shift changes are observed when Pin1 and 2xP are mixed in solution, at 
different ratios of protein to peptide, up to a ratio of 1:2. Figure 9A shows the HSQC 
spectrum of Pin1 protein depicted by black peaks (Figure 9A – left panel) and the final 
titration spectrum of Pin1 with 2xP peptide depicted by green peaks (Figure 9A – right 
panel). The spectra are overlaid (Figure 9A – bottom panel) and residues that display 
visible peak shifts are labeled. The unassigned side chain peaks visible in the spectra are 
circled and indicated. When comparing the 
1
H-
15
N HSQC spectra for 
15
N-labeled Pin1, 
with and without 2xP peptide, 91 total peaks corresponding to backbone amide bonds 
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were revealed (Figure 9B). There are eleven peaks that shifted significantly in their 
position, indicative of a chemical shift greater than a 1ζ change, all of which are located 
in the WW domain of Pin1. Six of the aforementioned peaks show shifts greater than a 
2ζ change. These peaks underwent fast exchange and could therefore be tracked 
throughout the titration experiments. 
To appropriately define the main region of interaction between Pin1 and the 
doubly phosphorylated peptide, the chemical shift changes observed when 2xP peptide 
was bound to Pin1 were mapped to the three-dimensional (3D) structure of Pin1 
according to their magnitudes (Figure 9C). Residues are coloured using a gradient from 
cyan, representing little or no chemical shift change, to white to magenta, representing 
the largest chemical shift change. This result confirms that the WW domain of Pin1 is in 
fact the dominant binding domain in the protein.  
Notably, residue Arg14 exhibits the largest peak shift, through NMR experiments 
using wild type Pin1 protein, with a change greater than 4ζ, while the amino acids 
surrounding the arginine (Lys13, Met15 and Ser16) also show large changes. All peak 
shifts occurring after residue 35, which corresponds to the protein linker as well as the 
isomerase domain, exhibited less than a 1ζ chemical shift change (Figure 9B).  The 
residues with the largest peak shifts are predominantly mapped to the WW domain.  
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Figure 9 (A
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Figure 9 (B-C)  
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Figure 9 Caption 
 
  
Figure 9 
1
H- 
15
N HSQC NMR spectra of Pin1 and Pin1-2xP complex with the changing 
residues plotted and mapped to the 3D structure of Pin1. 
NMR spectroscopy titration experiments were conducted using wild type Pin1 and the 
doubly- phosphorylated 2xP peptide on a Varian Inova 600 MHz spectrometer with pulse 
field gradient triple resonance probes, at 25 ᴼC. A spectrum of protein alone (322 µM) was 
taken before adding in peptide, at 0.25 molar equivalents, to a final concentration of 2 molar 
equivalents of protein. (A) The plots depict protein sample peaks in black (left panel) with the 
Pin1-2xP at a ratio of 1:2 in green (right panel). The two spectra are overlaid in the bottom 
panel and residues that display visible peak shifts are labeled by amino acid and number. The 
peak assignment was done previously and deposited into the BMRB as file 5305
122
.The 
unassigned side chains peaks are circled and indicated.  (B) The graph presents the residues 
that exhibited chemical shift changes in Pin1 when 2xP peptide was added to the sample. The 
amount of peak shifting in both the 
1
H and 
15
N dimensions is depicted on the y-axis and the 
respective residue number on the x-axis. Dashed lines indicate standard deviations of 1 or 2. 
The WW domain residues are shaded grey and the chemical shift changes greater than 1ζ 
were limited to this domain. (C) Residues seen to have chemical shift changes, above 1 
standard deviation, upon 2xP peptide addition to Pin1 were mapped to the surface of the full 
length protein. The residues are coloured according to the magnitude of chemical shift change 
with cyan depicting no change or little change, white showing some change and the darkest 
purple showing the largest changes.  
56 
` 
Peak intensity changes were also observed in the 
1
H-
15
N HSQC spectra. In total, 
36 peaks displayed intensity changes greater than a 1ζ change, with 14 of those peaks 
having a heightened intensity with increasing amounts of peptide (Figure 10A).  All 
peaks exhibiting intensity changes are described to undergo slow or intermediate 
chemical exchange. These peaks were mapped to the structure of Pin1 (Figure 10B) and 
are visible on both faces of the protein.  Many residues from Ser16 to Glu51, located in 
the WW domain as well as the linker between both Pin1 protein domains, showed peak 
intensity changes; with clusters of changes occurring from Ser16 to Arg21, Asn26 to 
Glu36 (both in the WW domain) and Gly39 to Glu51 (in the linker region of the protein). 
In the PPIase domain, from residue Lys95 to Ser126, there were also a large amount of 
peak intensity changes; with clusters of changes displayed from Glu100 to Ser105, 
Ala107 to Cys113 and Arg119 to Gly123. On the C-terminus of the protein, there is a 
cluster of peak intensity changes from residue Ile156 to Leu160. Of note are the intensity 
changes on the catalytic Cys113, involved in peptide bond isomerization by Pin1, and 
Lys122 which is one of the amino acids that binds to the side chain of a substrate Pro. 
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Figure 10 (A-B) 
Figure 10 Pin1-2xP complex intensity changes seen by NMR and their locations 
mapped to the surface of Pin1. 
(A) The plot displays residues that underwent changes in intensity when the 2xP peptide 
was titrated into a solution of wild type full length Pin1. The dashed lines represent a 1ζ 
change from the mean, based on the standard deviation of the data. (B) Residues with 
intensity changes of ± 1ζ, upon 2xP peptide addition to Pin1, were mapped to the surface 
of the protein (grey). The residues are coloured in blue and are clustered throughout the 
protein.  Both sides of Pin1 are shown.  
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In summary, binding of the doubly-phosphorylated 2xP peptide derived from 
human CDC25C brought about critical changes in the WW domain of Pin1, as well as 
many slow or intermediate exchanges occurring through intensity changes in both the 
WW and PPIase protein domains. Amino acid residues Gly20, Arg21 and Asn26 in the 
WW domain were further analyzed in the hopes of determining a binding constant. The 
plot shows binding curves for the selected residues with corresponding Kd values 
(Appendix Figure A3).   
3.5 Pin1 does not bind to a non-phosphorylated peptide with 
high affinity 
Pin1 was also combined with the non-phosphorylated peptide (0xP) and 
1
H- 
15
N 
HSQC NMR spectra were collected following each peptide addition. The HSQC 
spectrum of Pin1 protein is shown as black peaks (Figure 11A - left panel), while the 
final titration point of Pin1 with 2 molar equivalents of 0xP peptide is shown as red peaks 
(Figure 11A - right panel). The spectra are overlaid for comparison of 
15
N-labeled Pin1, 
with and without 0xP peptide (Figure 11A – bottom panel). Although little change can 
be seen, 17 peaks that shifted in position were revealed (Figure 11B). Five of the 17 
peaks shifted less than a 1ζ change. Seven peaks shifted greater than a 2ζ change with 
residue Gln49 exhibiting the largest chemical shift change, a value greater than 4ζ. 
Residue Ser154, known to be involved in peptide bond isomerization, has a chemical 
shift perturbation of greater than 1.25ζ. The residues exhibiting chemical shift changes 
with the addition of 0xP were mapped to the 3D structure of Pin1 (Figure 11C), where 
the  residues are coloured using a gradient from cyan, representing little or no chemical 
shift change, to white to magenta, representing the largest chemical shift change. 
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Figure 11 (A) 
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Figure 11 (B-C) 
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Figure 11 Caption  
 
Figure 11 
1
H- 
15
N HSQC NMR spectra and chemical shift data for Pin1 and the Pin1-
0xP complex.  
NMR spectroscopy titration experiments were conducted using wild type Pin1 and the non-
phosphorylated 0xP peptide on a Varian Inova 600 MHz spectrometer with pulse field 
gradient triple resonance probes, at 25 ᴼC. A spectrum of protein alone (322 µM) was taken 
before adding in peptide, at 0.25 molar equivalents, to a final concentration of 2 molar 
equivalents of protein. (A) The plots depict protein sample peaks in black (left panel) with 
the Pin1-0xP at a ratio of 1:2 in red (right panel). The two spectra are overlaid in the bottom 
panel, showing virtually no peak shifts. The peak assignment was done previously and 
deposited into the BMRB as file 5305
122
. (B) The graph presents the residues that exhibited 
chemical shift changes in Pin1 when 0xP peptide was added to the sample. The amount of 
peak shifting in both the 
1
H and 
15
N dimensions is depicted on the y-axis and the residue 
number is on the x-axis. Dashed lines indicate standard deviations of 1 or 2. The WW 
domain residues are shaded grey. Both domains have residues with chemical shift changes 
larger than 1ζ. (C) Residues seen to have chemical shift changes above 1 standard 
deviation, upon 0xP peptide addition to Pin1, were mapped to the surface of the full length 
protein. The residues are coloured according to the magnitude of chemical shift change 
with cyan depicting no change or little change, white showing some change and the darkest 
purple showing the largest changes.  
62 
` 
An additional 24 peaks exhibited intensity changes larger than a 1ζ change, when 
0xP peptide was mixed with the protein (Figure 12A). Notably, several of these residues 
are located in the linker between the WW and PPIase domains. These residues have been 
mapped to the structure of Pin1 (Figure 12B).  The results indicate that the affinity of 
Pin1 to a non-phosphorylated substrate is weak, because few protein residues are heavily 
impacted by the addition of the 0xP peptide. The linker domain residues exhibit the 
largest peak intensity changes overall, but neither of the protein domains are affected. In 
summary, these results indicate that NMR, a commonly used method to detect protein 
interactions, cannot identify a change in any particular region of Pin1 upon 0xP binding.  
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Figure 12 
 
 
 
Figure 12 Pin1-0xP complex intensity changes observed by 
1
H- 
15
N HSQC NMR and 
their locations mapped to the surface of Pin1. 
(A) The plot displays residues that underwent changes in intensity when the 0xP peptide 
was titrated into a solution of wild type full length Pin1. The dashed lines represent a 1ζ 
change from the mean, based on the standard deviation of the data. (B) Residues shown 
to have intensity changes ± 1ζ, upon 0xP peptide addition to Pin1, were mapped to the 
surface of the protein (grey). The residues are coloured in blue and are mostly clustered 
to the linker region of the protein, between the WW and PPIase domains.  Both sides of 
Pin1 are shown.  
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3.6 The number of phosphorylation sites affects Pin1-CDC25C 
peptide interactions 
Dissociation constants from Pin1 binding to CDC25C-derived peptides were 
calculated through in vitro fluorescence polarization assays, using fluorescein-labeled 
peptides. Fluorescence polarization is a biophysical method used to study protein-protein 
interactions. FP provides information regarding the binding of a tracer or dye to a protein, 
in solution. The light emitted by a fluorophore gives off a different intensity compared to 
excitation light
119
. The former light can be measured and quantified to determine binding 
of the labeled construct to a protein. 
The affinities of labeled 0xP and 2xP are substantially different and can be seen 
visually as well as determined quantitatively using a curve for specific binding (Figure 
13).  The affinities calculated for both of the singly-phosphorylated 1xP peptides are 
similar. However, 1xP #2 does have a lower binding constant and therefore Pin1 has a 
higher binding affinity towards this peptide.  The FP experiments for all of the peptides 
display specific one-site binding curves with the Kd values depicted in Table 2. The data 
illustrates that an increased number of phosphorylation sites, as well as the location of the 
site, does impact the interaction between full length Pin1 and the CDC25C-derived 
peptides.  
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Figure 13 (A-B) 
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Figure 13 (C-D) 
 
Figure 13 Fluorescence polarization experiments of Pin1-peptide complexes. 
NHS-fluo scein-labeled 0xP (A), 1xP #1 (B), 1xP #2 (C) and 2xP (D) CDC25C-derived 
peptides were combined with increasing amounts of wild type Pin1 protein to determine a 
binding constant. Wild type Pin1 was increased by a factor of two per titration point. Each curve 
is the average of three experiments, completed in duplicate, with error bars representing the 
standard deviation. Each graph was analyzed using a curve for specific one-site binding, as a 
function of protein concentration. Table 2 shows the binding constants determined from analysis 
of the assays. 
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Table 2 Fluorescence polarization experimental results of the human CDC25C- 
derived peptides synthesized to test binding affinities to Pin1 protein in vitro. 
The binding constant (Kd) value for each of the Pin1-peptide interactions was tested with 
NHS-fluorescein labeled peptides, in duplicate for three separate reactions. Each data set 
was analyzed using a non-linear regression for single-site specific binding, based on the 
protein concentration. 
 
 
  Shorthand Peptide Notation Kd (M) 
0xP 2253  
1xP #1      391.6  
1xP #2      272.8  
2xP          85.21 
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4. Discussion 
Pin1 is characterized as a dual-domain isomerase, as it is composed of a WW 
binding domain and a peptidyl-prolyl isomerization domain. Both domains bind to 
similar pSer/Thr-Pro motifs, which increase the complexity of the system
45,88
. How Pin1 
is capable of using this multi-site binding and substrate isomerization to regulate key 
signal transduction pathways is of utmost importance to aid in targeting diseases such as 
cancer.  
Studies in the field of human Pin1 as a mitotic regulator began with the 
interaction of NIMA
21
, followed by interactions with CDC25
23,24
. Phosphorylation and 
Pin1 affect CDC25C, as the phosphatase is subjected to both positive and negative effects 
of phosphorylation
24,98,129
. Pin1 catalyzes the isomerization of CDC25C which promotes 
its dephosphorylation. CDC25C then becomes inhibited without the phosphate moiety 
and early entry into mitosis is stalled
127
. It has been demonstrated that full length Pin1 is 
necessary for the interaction with CDC25C
95
. Thus, in order to bind both phosphorylation 
motifs on the substrate at the same time, two sites on Pin1 would be required, potentially 
one on each domain.  
Mitotic regulation by Pin1 can be explained in a two-step mechanism. First, a 
Ser/Thr-Pro motif becomes phosphorylated by the mitosis-specific activation of a protein 
kinase. Pin1 is next able to bind to the phosphorylation site and conduct isomerization, to 
promote a conformational change in the substrate
24
. This change in a phospho-protein can 
alter binding capabilities, enzymatic activity or function as observed for CDC25
23,24
. Not 
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only is Pin1 implicated in mitosis, but it has a role in cell proliferation and cancer as well 
as a role in the reversal of neurodegenerative disorders
38
.  
4.1 Pin1-CDC25C interactions 
The Pin1-CDC25C interaction has been well characterized in the 
literature
23,88,94,97,104,127
. This association is important in the initiation of mitosis and if 
unregulated, the overexpression of both proteins separately can result in cancerous 
phenotypes
8,38,130,131
. The cellular concentrations of both proteins do not fluctuate during 
cell cycle progression
23,132,133
, in contrast with many proteins involved in the identical 
processes 
134-136
. Preceding mitosis, the interaction is maximal and is mediated by the 
phosphorylation of CDC25, which activates the pathway.  Following activation, the 
activity of CDC25 is inhibited to similar levels as observed for the phosphatase during 
interphase
24
. The aforementioned results implicate Pin1 as a regulatory protein in mitosis. 
Pin1 is suggested to disable the early entry into mitosis, induced by the NIMA kinase. In 
addition, overexpression of Pin1 generates a mitotic G2 phase arrest phenotype
21
. Not 
only does Pin1 negatively regulate mitosis, but it positively affects this process as well 
since it is required for progression through mitosis
23
.  
The relationship between Pin1 and CDC25C was first identified through a study 
of Pin1 interactions with mitotic phospho-proteins
23
. The CDC25C-Pin1 interaction 
occurs in the presence of both Pin1 protein domains, with each domain in its entirety 
containing key residues for binding and catalysis.  The CDC25C protein is 
phosphorylated at three Thr sites in vivo, Thr48, Thr67 and Thr130
137
, with the former 
two residues involved in Pin1 binding when phosphorylated
88,127
.  A pThr peptide 
mimicking the human CDC25C sequence surrounding residue Thr48 specifically binds to 
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the WW domain of Pin1
88
. The peptides generated for the present study were derived 
using the known Pin1 binding motifs, taken from the protein sequence of human 
CDC25C surrounding Thr48 and Thr67 which are both pThr-Pro sites
88,127
.  
4.2 Effects of peptides on Pin1 global conformation 
As an initial step towards understanding the binding between Pin1 and CDC25C, 
the CDC25C-derived peptides were mixed with protein and the complexes were used to 
detect global changes within the protein. The overall conformation of Pin1 in solution did 
not change with the addition of peptide, measured based on the derived sedimentation 
coefficients for samples of protein alone and protein-peptide complexes, at molar ratios 
of 1:1 and 1:2 protein to peptide.  
4.3 Protein stability did not change when peptides were added  
The stability of Pin1 was neither increased nor decreased upon addition of the 
CDC25C-derived peptides, based on the secondary structural elements of the protein and 
its melting temperature. Of mention from the CD experiments was the noise visible in the 
spectra ranging from 180 to 210 nm. This noise is caused by a large high tension voltage 
on the spectropolarimeter, a value that increases as the wavelength being scanned 
decreases into the far ultra-violet range
138
. When the high tension voltage rapidly 
increases and the photo-multiplier tube reaches a saturation voltage, artifacts may be 
perceived in the sample
139
.  These observations may impact the conclusion drawn from 
CD experiments, because the 180-200 nm spectral range shows differences between the 
examined samples. This may affect the secondary structure of Pin1, although the protein 
stability between samples remained the same. The hypothesis of two phosphorylated 
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binding sites increasing the binding affinity of Pin1 towards CDC25C-derived peptides 
remains plausible because the 2xP peptide does not decrease protein stability.  
4.4 Pin1 has a higher affinity for phosphorylated peptides 
The phosphorylation of Ser/Thr–Pro motifs impairs catalytic isomerization by 
cyclophilins and FKBPs. In contrast, Tyr-Pro sequences are susceptible to this 
isomerization
8
. The novel parvulin-family PPIase Pin1 preferentially isomerizes Pro 
residues preceded by phosphorylated Ser or Thr with up to a 300-fold increase in kcat / 
Km, compared to its non-phosphorylated counterpart. Pin1 is therefore both a sequence-
specific and phosphorylation-dependent enzyme
8
. For this reason, parvulins and Pin1 in 
particular, with specificity towards phosphorylated substrates, play important roles in 
cellular processes including the regulation of mitosis
8
. The results obtained by NMR 
using the doubly-phosphorylated CDC25C-derived peptide showed visible chemical shift 
changes indicative of peptide binding to Pin1. Residue Arg14 exhibited the largest peak 
shift when the 2xP peptide was bound. The amino acids Lys13, Met15 and Ser16 that 
surround the Arg also exhibited large peak shift changes (Figure 9). This is 
representative of the WW domain binding to the peptide with high affinity, consistent 
with a previous study where the WW domain was shown to have approximately a ten-
fold stronger affinity for a substrate than the PPIase domain
88
.   
Intensity changes are caused by slow or intermediate chemical exchange
115
 when 
a substrate is added to Pin1. Peak intensity changes were displayed in each region of the 
protein with the addition of 2xP. This finding may relate to the binding of both 
phosphorylated motifs in the peptide, one to each of the Pin1 domains, as peak intensity 
reflects the speed at which molecules tumble in solution
116
. The central peptide residues 
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between the two binding motifs likely interact non-specifically with the protein linker. 
Through the use of both chemical shift and peak intensity data, local changes in Pin1 that 
occur on different time scales can be resolved
115
, as each residue in the protein will 
behave differently. 
Experiments examining the binding of peptides to Pin1 were able to detect 
interactions, when protein concentrations of up to 800 µM were used. Each peptide was 
labeled with NHS-fluorescein, to display a fluorescein tag on the N-terminus that could 
be visualized at the appropriate wavelength. This tag is unlikely to interfere with the 
protein-peptide interaction due to its location on the N-terminus of the peptide, which is 
seven residues away from the first binding site, and the cyclic nature of the label has little 
mobility.  
Singly-phosphorylated peptides, containing the same CDC25C-derived sequence 
as the 2xP peptide, were designed to test the binding affinities of full length Pin1. 
Literature on the topic of Pin1 describes other singly-phosphorylated CDC25C peptides 
which yield diverse affinities towards the protein. The altering affinities are likely a result 
of amino acids surrounding the phosphorylated residue
104
. The peptide sequence 
VPRpTPV (CDC25C-Thr48)
104
 has a binding affinity of 80-fold higher than that of the 
1xP #1 peptide, also surrounding the Thr48 site. Both peptide-protein affinities are 
comparable due to being measured by fluorescence polarization. The VPRpTPV peptide 
is six residues in length, shorter than the 32 residue 1xP #1 peptide. The shorter peptide 
and one Pin1 protein domain are likely to bind, as the WW domain recognizes up to five 
amino acids
104
 and the PPIase domain binds strongly to five residue peptides
106
. Due to 
the small size of the VPRpTPV peptide, it can remain inflexible and tightly bound to 
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Pin1, increasing the polarization of light in a fluorescence polarization experiment. 
Conversely, the binding of either Pin1 domain to the pThr site on either the 1xP #1 or 
1xP #2 peptide may not be able to stabilize the extra 25 unbound peptide residues to 
polarize light sufficiently. For this reason, the binding affinities for the 1xP-Pin1 
interactions would appear to decrease in comparison to the previously reported values by 
Verdecia et al. for the VPRpTPV peptide
104
. 
The studies presented here analyzing the binding curves, and therefore binding 
affinities, of Pin1 towards a common CDC25C-derived peptide with varying amounts of 
phosphorylation indicated that an increase in the number of phosphorylation sites 
correlates with a decrease in Kd values. An increase in peptide phosphorylation from zero 
to one correlates with an increase in binding affinity, based on a decrease in Kd values 
from 2253 µM to approximately 330 µM (averaged from both singly-phosphorylated 
peptides). This is indicative of phosphorylation-dependent binding between Pin1 and the 
peptides. A study using mutations of CDC25C residues Thr48 and Thr67 to Val, an 
amino acid that cannot be phosphorylated, has shown that binding to full length Pin1 is 
abolished
127
. 
Interestingly, the singly-phosphorylated CDC25C-derived peptides used in the 
present study exhibited different binding affinities based on the location of their 
phosphorylation site (see Table 1 for the peptide sequences). With the phosphate moiety 
located at site #2 on the peptide, the Kd value was decreased by more than 100 µM, 
indicative of a higher affinity. This result is likely due to the chemical environment 
surrounding the phosphate. Two small Gly residues are preceding the pThr, which could 
enable binding due to a lack of steric clashes, compared to the Arg residue preceding the 
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site #1 phosphate. The residues that appear after the pThr-Pro motif also differ at site #1 
and site #2, as they are a Val and a Lys, respectively. This difference in hydrophobicity 
as well as charge may impact binding. 
There is weak binding of full length Pin1 to the non-phosphorylated CDC25C-
derived peptide, depicted by a dissociation constant of 2253 µM measured by 
fluorescence polarization. This binding may be attributed to the promiscuity of the WW 
domain of Pin1, as this domain is the main binding domain of the protein and may be 
responsible for nonspecific interactions
140
.  
Residues impacted by the addition of peptides to Pin1 are seen to localize to 
different regions of the protein based on the number of phosphorylation motifs available 
(Figures 9 and 11). Upon binding of the non-phosphorylated peptide, the linker region of 
the protein showed several peak intensity changes. This observation is feasible because 
the linker of Pin1 is flexible
36
 and may enable nonspecific binding, while both of the 
protein domains are phosphorylation specific.  
4.5 Two phosphorylation sites further increase Pin1-peptide 
binding affinities 
Overall, the increase of phosphorylation sites on the CDC25C-derived peptides 
from zero to one and one to two increases the binding affinity towards Pin1. The 
dissociation constant measured in the present study for the Pin1-2xP interaction was 
85.21 µM, a smaller Kd value than those determined for the 0xP and 1xP peptides. This 
incremental increase in binding affinities is similar to the results observed in the literature 
from other known Pin1-interacting proteins. With the addition of a phosphate moiety to a 
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singly-phosphorylated sequence, peptides derived from the C-terminus of RNA 
polymerase II and from Tau exhibit an increased binding affinity
90,104
. An example of 
increased binding affinities towards doubly-phosphorylated substrates from the literature 
was shown using Tau-based peptides
49
.  
The present study has determined dissociation constants for full length Pin1 with 
the CDC25C-derived peptides, but it would be beneficial to investigate the binding of 
each Pin1 domain to the peptides. The WW domain alone would likely bind to the 
peptides, because of its hydrophobic pocket that coordinates substrate binding
88
. It is 
difficult to conclude whether the PPIase domain alone would bind to the peptides, as 
there would be approximately 25 residues of free peptide tumbling in solution.   
4.6 Peptide binding to individual Pin1 domains 
The PPIase domain of Pin1 is known for its catalytic function rather than 
substrate binding efficiency. In vitro studies have shown that this domain is usually 
unable to bind phospho-proteins
88,95
, although substrate specificity is required to bind a 
sequence for isomerization. Substrates may only have temporary interactions with the 
PPIase domain, upon bond catalysis. This is a probable option, as the Pin1 active site has 
been shown to be prepared for catalysis and amino acid exchange processes, even in the 
absence of a substrate
141
. 
In contrast to the PPIase domain, the WW domain binds to peptides derived from 
substrates with dissociation constants in the low micromolar range, from approximately 1 
to 150 µM
88,104,142
. The large ranges of dissociation constants observed for interactions of 
peptides with full length Pin1 and each of the Pin1 domains suggests that binding 
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affinities are variable and depend on factors such as peptide length, sequence and 
phosphorylation states. In some cases, individual protein domains may be incapable of 
binding to a given peptide. Many Pin1 interacting proteins have been shown to require 
both the WW and PPIase domains to associate with Pin1 and successively perform their 
enzymatic or regulatory functions. Proteins that fall into this category include:  protein 
kinases CK2
143
 and PLK1
32
, the transcription factor c-Jun
41
 and tumour suppressor 
p53
144
. 
4.7 The WW domain of Pin1 acts as the main binding domain  
Residues Ser16, Arg17, Tyr23 and Trp34 on the surface of Pin1 form the 
hydrophobic binding pocket observed to enable the characteristic binding properties of 
the WW domain
88
. Through NMR experimentation using the changes in peak chemical 
shifts by 
1
H-
15
N HSQC, the present study demonstrates that the doubly-phosphorylated 
peptide binding to Pin1 affects the WW domain only. However, the PPIase domain may 
exhibit much weaker affinities for the peptides which could be overlooked as the changes 
in peak chemical shifts are not the sole method to determine interactions by NMR. 
Studies from the literature have pointed out that the WW domain shows binding affinities 
of approximately ten-fold stronger than those of the PPIase domain, in vitro
88,90
.  For this 
reason, the WW domain is thought to augment substrate specificity and function as the 
protein-targeting domain.   
It is likely that binding of the second phosphorylation site in the CDC25C-derived 
peptide 2xP is too weak to detect through NMR, based on the protein and peptide 
concentrations used in the present work. Once the peak intensity changes from the NMR 
data have been taken into account, both domains display changes likely attributed to a 
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single phosphorylation site located in each of the two protein domains. Taken together, 
both the chemical shift changes and peak intensity data display the overall effects of 
Pin1-peptide binding. 
4.8 Kd values compared to literature values 
Dissociation constants for full length Pin1 binding to a variety of substrate 
peptides were measured previously, using fluorescence polarization, and the values 
ranged from 5 to approximately 80 µM. These peptides were presented by Verdecia et 
al., derived from known Pin1 interacting proteins of physiological relevance, were 
between six and eight amino acids in length and contained from zero to two 
phosphorylation sites
104
. One specific example was the examination of the binding 
affinity between Pin1 and an RNA polymerase II, C-terminal domain peptide, when the 
peptide contained two distinct phosphorylation sites separated by two amino acids (Table 
3). The small separation between phospho-sites and the short total peptide length seem to 
impact binding, considering the Kd measured for this interaction was 10 μM
104
. Of note 
are the examined pSer residues, as pSer-Pro motifs bind to Pin1 with lower affinity than 
pThr-Pro motifs
145
.  However, the isomerase activity of Pin1 for pSer-Pro motifs is 
higher
8
.  This may be a result of the conformations adopted by each of the 
phosphorylated residues
146
.   
Another study looked at a 40 residue peptide, derived from the Pin1-interacting 
protein Tau, which contained three phosphorylation sites (Table 3). When tested for 
binding to Pin1, a dissociation constant of 70 μM was measured for this  interaction90.  
Two of the phosphorylated residues in this peptide sequence were spaced apart by 16 
78 
` 
amino acids, suggesting that phosphorylated motifs are separated for a reason, potentially 
to improve substrate binding to Pin1.  
An additional study looking into the binding of bivalent peptides to Pin1 was 
conducted in 2007, by Daum et al. These peptides were generated to target the Pin1 
domains specifically (Table 3) and would only bind in a single orientation
147
.  Using 
isothermal titration calorimetry, the dissociation constants determined for these peptides 
were all between 400 and 800 nM. These peptides contained a single Pin1 binding motif 
and a Pro-rich linker, with the latter not found in natural Pin1-binding proteins
147
. The 
optimally-designed peptides were generated for the purpose of specific domain binding. 
It is understandable why these peptides would bind to Pin1 with a higher affinity than 
other peptides, including those used in the present work.  
In comparison to the aforementioned data by Daum et al. and Verdecia et al., the 
Kd values obtained from the CDC25C-derived peptides in the present study were:  2253 
µM for the non-phosphorylated peptide, 391.6 µM for 1xP #1, 272.8 µM for 1xP #2 and 
85.21 µM for the doubly-phosphorylated peptide.  These binding affinities are all lower 
than those observed in the literature, potentially due to the length of the peptide 
sequences. Table 3 shows a peptide from each study, for direct comparison, and 
highlights the features of each. All the peptides, excluding the synthetic peptide, were 
derived from physiologically relevant Pin1-interacting proteins and contain multiple Pin1 
binding motifs. The binding affinities measured for the three protein-derived peptides are 
all of the same order of magnitude. The CDC25C-derived peptide spans both Pin1 
domains, similarly to the Tau peptide.  
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Table 3 
 
Table 3 Peptides used in the literature compared to the 2xP peptide used in the 
present study.  
The peptide sequences are listed, with the phosphorylated residues in bold and red. The 
binding constant (Kd) value for each of the full length Pin1-peptide interactions is also 
shown. 
 
Peptide sequence Number of 
Residues in 
Peptide 
Peptide Source Kd (µM) Citation 
YpSPTpSPS 7 RNA Pol II 
(CTD-S2/S5) 
10 Verdecia, 
2000104 
GSPGTPGSRSRpTPpSLPTPPTREPK
KVAVVRpTPPKSPSSAK 
40 Tau 
(T212/S214/T231) 
70 Smet, 
200590 
Ac-FE-Pip-Nal-Q(P)6A-Bth-pTP-
Cha-Q-NH2 
17 Synthetic 0.804 Daum, 
2007147 
CPDVPRpTPVGKFLGDSANLSILSGG
pTPKRSLD 
32 CDC25C 
(T48/T67) 
85 Present 
study 
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4.9 The distance between phosphorylated residues impacts 
binding 
Studies observing the effects of phosphorylated peptide binding to Pin1 have been 
described in the literature, containing shorter sequences as well as different spacing 
between phosphorylation sites
49,90,104
. The distance between the phosphorylation sites in a 
peptide seems to impact binding and substrate affinities towards Pin1.  The peptides used 
in this study have a 19 amino acid separation between phosphorylation sites.  
A protein containing 19 residues between Pin1 interaction sites, similarly to 
CDC25C, is the Tau protein involved in microtubule stabilization in neurons
49
. Tau and 
its interactions with Pin1 have been well studied in the literature for their involvement in 
Alzheimer’s disease49,56,90,127. Residues Thr212 and Thr231 are both followed by a Pro 
residue and can be phosphorylated to be targeted by Pin1. As Tau-derived peptides have 
already been studied
56
, a logical next step would be to confirm the results in vitro using 
full length proteins and subsequently in vivo. It would be interesting to see whether the 
requirements for Tau binding to Pin1 are similar to those of CDC25C.  
In 2007, Daum et al. used a bivalent peptide to study Pin1-substrate interactions. 
This peptide was shown to have up to a 350-fold increase in affinity towards Pin1, 
compared to a monovalent peptide
147
. Another key finding from this paper was the 
determination of an optimal linker length. Five Pro residues between the two Pin1 
domains presented the highest affinity. Changing the linker length between the two 
binding motifs of a doubly-phosphorylated peptide, to obtain an increased affinity, could 
be elaborated as future work of the present study. In contrast to the present study, the 
peptides generated by Daum et al. only contained a single phosphorylation site. The use 
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of a doubly-phosphorylated human CDC25C-derived peptide is therefore unique and has 
given insight into a different form of bivalency.  
Enhanced binding to Pin1 has been proposed as a result of cooperativity between 
phosphorylation sites, commonly spaced between 18 and 22 amino acids apart from one 
another in a sequence
148
. The peptides used in the present study have a spacing of 19 
residues between binding motifs, which ideally promotes cooperative binding. In short, it 
seems improved Pin1 binding is determined by the number and positioning of 
phosphorylated residues.  
4.10 Pin1 binding to phosphate moieties 
Phosphate buffers were used in certain present study experiments in order to 
directly compare the results to previous studies
79
. The buffers used for NMR experiments 
were the same as those used in the Duncan et al., 2011 paper, as the protein amide HSQC 
peaks had been previously assigned
122
. The phosphate concentration in the buffer was 
diluted for CD experiments to avoid background noise from excess phosphate, while the 
CD experiments were conducted to ensure the Pin1 protein was folded for the NMR 
experiments. As Pin1 is phosphorylation-dependent, the phosphate molecules in the 
buffer could have affected binding to the peptides. The peptide titration results do show 
Pin1-peptide interactions with affinities in the micromolar range, which indicates that 
binding still occurs in the presence of excess phosphate. This is likely due to the absence 
of the proper Pin1 binding motif in the buffer. With this in mind, the fluorescence 
polarization experiments were conducted in a HEPES buffer to avoid the potential for 
excess phosphate binding to Pin1 and misrepresentations in the data.  
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4.11 Effects of molecular crowding on Pin1 binding 
A recent study conducted by Luh et al. discussed the effects of molecular 
crowding on substrate binding by the WW domain of Pin1. The study examined Pin1 in 
Xenopus laevis oocytes and in oocyte extracts crowded with proteins, through in-cell 
NMR experiments. The substrate recognition motif on the surface of the N-terminal Pin1 
domain is able to form weak, nonspecific interactions with endogenous cellular 
proteins
140
.  The researchers used a Pin1 intracellular concentration of 150 μM, which is 
higher than that of specific Pin1 substrates. NMR signal loss, resulting from a longer 
rotational correlation time, was seen when only the WW domain was inserted into the 
oocytes. This observation implicates the WW domain in non-specific interactions that 
push Pin1 into large in vivo complexes. The NMR line broadening results obtained were 
therefore concluded to be due to nonspecific interactions
140
. Additional proteins added 
into the oocyte samples, to act as crowding agents, revealed further weak and nonspecific 
interactions with Pin1, implicating permanent interplay between endogenous proteins
140
. 
Consequently, it is crucial to explore Pin1 binding to CDC25C and CDC25C-derived 
peptides in vivo as a method to understand the binding affinities when competing 
molecules are available. 
4.12 Pin1 binding model 
The interactions observed in the present study between the doubly-phosphorylated 
peptide and Pin1 require both protein domains to bind two separate motifs. This was 
suggested by NMR studies that revealed peak intensity changes in both Pin1 domains 
upon 2xP peptide titrations (Figure 10).  Neither the catalysis-first binding model nor the 
multimeric binding model seem to fit this data (Figure 3A-B), because there is no 
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indication of the PPIase domain binding to the peptide first and these experiments were 
performed using purified components without excess cellular proteins with which to form 
complexes. The sequential binding model (Figure 3C), which accounts for differential 
binding affinities between both Pin1 domains, is plausible for Pin1 interactions with the 
singly-phosphorylated peptides, due to a single available site for binding by the WW 
domain and then once released, isomerization can occur at the same site. This same 
method also accounts for Pin1 substrates with multiple binding motifs, where the WW 
domain binds to a target sequence first and the PPIase domain is free to catalyze the 
isomerization of other sites in the same molecule
19
.  However, the Pin1 domains 
individually were shown to be incapable of binding full length CDC25C
95
. This provides 
evidence against the sequential binding model, as CDC25C would need to be initially 
targeted by the Pin1 WW domain alone. The results of the present study promote the 
simultaneous model (Figure 3D) for binding of Pin1 to CDC25C-derived peptides, as 
was previously suggested by Innes et al. This model states that the binding of each 
pSer/Thr-Pro motif may be weak individually, but the binding of both sites at the same 
time can increase the overall affinity
95
.  
In comparison with the CDC25C-derived peptides, the Tau peptides may interact 
with Pin1 using a different binding model.  It would be of interest to compare the binding 
models of the peptides through binding studies using the individual Pin1 domains. To 
further advance the aforementioned study, one could characterize the binding of Pin1 to 
other known substrates. Determining the differences between protein substrate sequences 
and their corresponding protein domain interactions could give insights into Pin1-ligand 
binding modes, as this was described in previous work to affect binding
36
. 
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4.13 Future directions for the present work 
Testing the binding of the CDC25C-derived peptides with each individual Pin1 
domain would be a logical next step to understand how Pin1 interacts with a substrate. 
This can be accomplished by applying the same FP experiments as discussed in section 
2.8, using the WW and PPIase domains individually instead of wild type full length Pin1. 
Studies from the literature have presented the idea of Pin1 domain-specific peptide 
binding where both domains can bind a peptide but exhibit differing affinities
104
.  Several 
peptides had no detectable binding to the PPIase domain, while the peptides that did bind 
to this domain had dissociation constant values ranging from approximately 85 to greater 
than 500 µM
104
. Some X-ray crystallographic data has also presented structures with 
peptides bound to the PPIase protein domain of Pin1
45,107
.  
Not only could the individual domains of Pin1 be tested for binding to the 
peptides, but domains containing mutations that render them binding-deficient could also 
be examined. A Tyr23Ala mutation affects the hydrophobic patch on the WW domain 
that impacts binding
88
, while mutations Arg68/69Ala affect the basic cluster of the 
PPIase domain, also shown to impact binding
23
. These mutations could be generated on a 
full length Pin1 construct to test binding of the CDC25C peptide set used in the present 
study. It is reasonable to hypothesize that the domain mutants would each bind to a 
singly-phosphorylated peptide with a similar affinity to that exhibited by wild type 
protein, because only one domain of the wild type would be involved in the interaction.  
The doubly-phosphorylated peptide would expectantly bind to the mutant protein at a 
single site, leaving a large portion of the peptide mobile in solution. Through 
fluorescence polarization, the polarization of light could remain minimal and this may 
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affect assay results. With two functional domains, the protein will have a better chance of 
binding the 2xP peptide and increasing its binding affinity.  
Another future study should look into a preferential sequence of substrate residues 
to increase binding to Pin1. In 1997, Yaffe et al. discovered that peptides with an Arg 
residue at the Pro + 1 position were more efficient, as their kcat / Km values increased up 
to 1300 times those of their non-phosphorylated equivalents
8
. A thorough analysis of 
amino acid residues located between the Pin1 binding motifs should therefore be 
performed, using a peptide walking series, to determine optimal residues at each position.  
Binding affinities could also be determined using isothermal titration calorimetry 
(ITC). This technique was explored in the early stages of the present study, but the 
protein and peptide concentrations used did not generate a saturated binding curve. ITC 
requires high protein and ligand concentrations as well as a large volume of sample in the 
syringe if binding is in the high micromolar range. For the aforementioned reasons, this 
technique was not a feasible option. 
As previously mentioned, one interesting future direction for the present work 
would be to generate peptides of different linker lengths between the two binding sites. 
Although, in a few known Pin1 substrates the distance between the two phosphorylated 
motifs is 19 amino acids, the linear peptide may not have the ability to generate any 
structural folds to aid in binding. Using a Pro linker was seen to optimize bivalent peptide 
binding, as proline residues are known to impact structure
147
.  Varying the linker length 
of peptides may be useful to increase the protein-peptide binding affinity
147
. 
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Using shorter peptides to study Pin1 interactions may be useful, because a short 
peptide length could decrease flexibility upon Pin1 binding and could provide a different 
affinity for the binding outcome. The total peptide length and the length of the peptide 
sequence between Pin1 binding motifs are both important factors when generating 
peptides that bind optimally to the protein. Peptides of varying sizes could be generated 
and tested for binding to Pin1.  
CDC25C is one of many Pin1-interacting proteins that contain multiple Pin1 
binding motifs. Finally, it would be valuable to take a subset of such proteins and 
examine their sequences between binding sites, lengths and potential modes of binding. 
These key features will be useful in the generation of optimal Pin1-binding peptides that 
could act as specific protein inhibitors. 
4.14 Summary 
The present study aimed to determine any changes within the protein Pin1 when 
interacting with peptides derived from the phosphatase CDC25C, as well as the binding 
affinities associated with each Pin1-peptide complex. Pin1 did not exhibit global 
conformational changes when bound to any of the CDC25C-derived peptides, nor did the 
stability of the protein alter upon binding of the non-phosphorylated or doubly-
phosphorylated peptides. An increased affinity was observed, by two separate 
biochemical techniques, when the peptides contained a phosphorylation site. This result 
is consistent with findings from the literature stating that Pin1 is phosphorylation-
dependent
8,149,150
. To further this conclusion, Pin1 was seen to bind to a doubly-
phosphorylated substrate with a higher affinity than either of the 1xP peptides. The 
binding of the 2xP peptide was presented as bound to the WW domain predominantly, 
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through NMR peak chemical shifts changes, yet peak intensity data implicated the WW 
domain, linker region and PPIase domain of Pin1 in binding. It is therefore likely that the 
doubly-phosphorylated peptide bound simultaneously to the two Pin1 domains, as the 
binding affinity was increased with two pThr-Pro motifs on a single peptide.  
Multiple binding models for Pin1 interactions with substrates have been 
previously proposed
94,95
. This work has promoted the simultaneous model for Pin1 
binding with CDC25C-derived peptides, although other models may still apply. 
Considering the dual-domain binding nature of Pin1, it is reasonable to assume that 
substrate proteins comprised of varying numbers of binding sites would bind to Pin1 
differently, potentially through diverse binding models. The use of binding models could 
lead to an additional mode of classification for known Pin1-interacting proteins.  
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Appendices 
Appendix A: Crystal structure of Cys113Asp Pin1 construct shows 
a residue change in the active site 
Crystals of purified Pin1 protein were generated using the R14A C113D construct 
(courtesy of Dr. Brian Shilton), which has the six N-terminal residues deleted to decrease 
protein flexibility as well as the characteristic Arg to Ala mutation at residue 14.  Residue 
Cys113 is located within the active site of the protein and has been reported to impact the 
catalysis of substrate isomerization
77
. Crystals were made by sitting drop method using 1 
µl of 18 mg protein mixed with 1 µl of the mother liquor precipitant solution from the 
well below, comprised of 2.4 M ammonium sulphate in 100 mM HEPES buffer pH 7.8 
and 1% polyethylene glycol 400 (Figure A2 ). R14A construct crystals have been 
previously described in the literature under similar conditions
45
, but the Cys113Asp 
mutation has yet to be presented in a high resolution 3D structure. The crystallographic 
data collection and refinement information is listed in Table A1. Figure A2-A shows the 
electron density contour maps of 2Fo-Fc (blue) and Fo-Fc (green and red representing 
positive and negative densities, respectively) surrounding the Cys113 residue, before 
changing the residue in the software to an Asp. The two green electron density blobs are 
associated with the Asp side chain and  fit into the contour map once the structure has 
been refined with Asp113 (Figure A2-B). 
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Table A1 Pin1 R14A C113D crystallographic data collection and refinement 
parameters. 
Table A1 
  
R14A C113D Pin1 
Number of atoms 1497 
  macromolecules 1228 
Resolution Range (Å) 
27.791 - 1.865 
(1.8901 - 1.8645)   ligands 49 
Space group P3121   water 220 
unit cell 
68.530 68.530 79.270 
90.00 90.00 120.00 Protein residues 145 
Total reflections 34415 RMS (bonds) 0.006 
Total reflections  
(non-anomalous) 
18281 
RMS (angles) 1.055 
Multiplicity 5.8 (5.4) Ramachandran favored 98.58 % 
Completeness (%) 98.5 (89.9) Ramachandran allowed 1.42 % 
Mean I / sigma (I) 24.3 (8.6) Ramachandran outliers 0.00 % 
Wilson B-factor 20.412 Clash score 5.10 % 
R-merge 0.045 (0.179) Average B-factor 22.3833 
R-meas 0.050   macromolecules 20.4619 
R-work 0.1829 (0.2674)   ligands 31.2879 
R-free 0.2179 (0.3076)   solvent 31.6173 
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Figure A2 
  
Figure A2 Pin1 C113D refined crystal structure. 
Zoomed in portion of R14A C113D Pin1 crystal structure showing residue C113 
with additional positive electron density (shown in green)  (A) and D113 with no 
additional electron density  (B) at 1.865 Å, illustrating difference maps with a 
2|Fo|-|Fc| contour map (blue) at 1.0 ζ and a |Fo|-|Fc| contour map (green/red) at 3.0 
ζ. (C) Three dimensional structure of R14A Pin1 C113D showing the WW 
domain (red), the PPIase domain (blue), the sulphate, PEG molecule and glycerol 
atoms (orange) and the catalytic Cys residue mutated to an Asp (green). 
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Figure A3 
 
 
Figure A3 Plot of select WW domain residues displaying peak chemical shift 
changes. 
Select residues in the WW domain were further analyzed in the hopes of determining a 
binding constant. Only the 
1
H dimensional chemical shift changes were used for this 
analysis. The plots show binding curves for the selected residues: Gly20, Arg21 and 
Asn26, with corresponding Kd values listed in the legend to the right. WW domain 
residues were plotted based on their changes in chemical shift as a function of peptide 
concentration. 
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